16th Conference of the International Society of Geriatric Oncology

"Geriatric oncology: a multidisciplinary approach in a global environment"

Final programme
The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology.

The Journal of Geriatric Oncology publishes original research articles, review articles, clinical trials, treatment guidelines, short communications and letters to the Editor.

2015 Impact Factor* 2.257

*Journal Citation Reports published by Thomson Reuters 2016

MAKE AN IMPACT! Get your research read.

- Publishing 6 issues per year!
- All accepted manuscripts are published online as Articles-in-Press within 2 weeks
- Open access publishing options available
- Worldwide dissemination through ScienceDirect: more than 55,000 articles downloaded in previous 12 months

Submit your paper online at http://ees.elsevier.com/jgo

Follow us on:
@OncologyAdvance

Follow us on:
facebook.com/oncologyadvance

For more information, please visit our website: www.geriatriconcology.net
Content

Venue floor plan 4
Welcome message 5
About SIOG 6-7
  SIOG Board 7
  SIOG Membership 8-9
What we do 10-11
  Scientific and educational projects 12-13
General conference information 14-15
Scientific programme committee and track leaders 17
Faculty list 19
CME accreditation 20
SIOG Awards 21-23
Programme at a glance 24
Detailed programme by day 25-30
  Pre-Conference - Wednesday, November 16, 2016 25
  DAY 1 - Thursday, November 17, 2016 25-27
  DAY 2 - Friday, November 18, 2016 28-29
  DAY 3 - Saturday, November 19, 2016 30-31
Scientific posters 32-37
Sponsor acknowledgement 39
Industry sponsored satellite session programme 40
Scientific displays 41
Sponsor and exhibitor profiles 42-44
Faculty disclosures 45-46
Venue floor plan

**Ground floor:**
Registration area, session rooms, exhibition and poster area, coffee breaks and lunch, speakers preview room.

**First floor** (not in picture):
SIOG Meeting room (Leonardo), ecancer interview room (Bramante),
Welcome address

Dear Colleagues,

Following the great success of the 2015 SIOG Annual Conference in Prague, it is our pleasure to welcome you to the 16th SIOG Annual Conference in Milan, Italy from November 17-19, 2016.

The mission of the SIOG Annual Conference is to bring together international experts in geriatric oncology to present the latest evidence based research in the care of older adults with cancer. Every year, the members of various Committees of SIOG work hard to provide an outstanding and attractive programme to enhance and expand the scientific and educational sessions for a large number of international experts in geriatric oncology.

This year, our 3-day scientific programme is articulated around the theme: “Geriatric oncology: a multidisciplinary approach in a global environment” and includes multidisciplinary sessions on solid tumours, haematological malignancies, new therapies, geriatric assessment, supportive care needs and an educational forum dedicated to nurses. Special emphasis will be put on international views and considerations varying in locations across the world.

Highlights of this year’s conference programme include a special partnership session with GIOGer (Gruppo Italiano di Oncologia Geriatrica) which will cover geriatric oncology in Italy and with EUSOMA (European Society of Breast Cancer Specialists) to emphasize the need for a multidisciplinary approach in older patients with breast cancer.

We will also introduce case based-sessions, round table discussions and debates.

The SIOG Annual Conference 2016 also includes special sessions in collaboration with its industry partners to present the latest data on therapeutics and their application in the older cancer patient. SIOG being dedicated to the development of allied health professionals and junior faculty, will recognise their important work with the SIOG Nursing & Allied Health and the SIOG Young Investigator Awards.

Milan was one of Europe's most important cities during the Middle-Ages, and the home of the most spectacular Italian courts during the Renaissance. It has played a considerable role in Italian cultural history, and is one of the country’s major art cities; not only is there the magnificent gothic Duomo, but many fine buildings, churches, and museums, without forgetting the lively contemporary art scene and the Scala, and some eye-catching modern architecture. In 2015, it has welcomed the Universal Exhibition showing its ability to envision a universal glance on topics of international importance as nutrition. Countless works of art are housed in Milan, most within walking distance of central Piazza del Duomo. A city to explore and love, full of treasures, fashion and a lively night life.

So, once again, welcome to Milan and to the 16th SIOG Annual Conference. We wish you a wonderful time!

Etienne Brain  
SIOG President

Ravindran Kanesvaran  
SIOG 2016 Scientific Programme Chair

Laura Biganzoli  
SIOG 2016 Local chair

Stefania Maggi  
SIOG 2016 Co-chair
About SIOG

The International Society of Geriatric Oncology, or Société Internationale d’Oncologie Gériatique in French, hence the acronym SIOG, was founded in 2000 and was officially registered as a not-for-profit organisation under Swiss law in October 2012. SIOG is a multidisciplinary society, including physicians in the fields of oncology and geriatrics, and allied health professionals and has over 1130 members in more than 75 countries around the world.

The founding members were: Paul Calabresi, Matti Aapro, Lazzaro Repetto, Martine Extermann, John Bennett, Riccardo Audisio, Lodovico Balducci and Silvio Monfardini.

Our mission and vision

Challenge: Major risk factor for cancer is age, and with the aging of the world population, a major epidemiologic challenge is ahead of us

Our goal: to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment of older adults with cancer

SIOG promotes efforts in 3 strategic directions: Education, clinical practice and research. These are addressed through the following goals and tools:

1. Education

<table>
<thead>
<tr>
<th>Goals</th>
<th>Tools</th>
</tr>
</thead>
</table>
| Dissemination of knowledge to maintain a high common standard of healthcare in older cancer patients | • Journal of Geriatric Oncology (JGO)  
• SIOG Annual Conference  
• SIOG Regional Forums (APAC, LATAM, USA, etc.)  
• SIOG Education handbooks on geriatric oncology and online e-learning modules  
• SIOG Treviso Advanced Course, Education Resources: SIOG-ASCO, Educational Geriatric Oncology Books  
• Close collaboration with highly and well-known cancer educational organisations  
• Constantly updated scientific resources that cover full spectrum of all relevant topics |
| Integrate geriatric oncology in the curricula for medical and nursing education to ensure a high standard of qualification for healthcare professionals | • SIOG Clinical guidelines*  
• SIOG Task Forces active in various fields of geriatric oncology to produce position papers, consensus statements or clinical practice guidelines* |
| Address the shortage of specialist oncologists/geriatricians & allied health staff in geriatric oncology | • Comprehensive geriatric assessment  
• SIOG Clinical guidelines* |
| Increase public awareness of the worldwide cancer in the elderly epidemic | • Comprehensive geriatric assessment  
• SIOG Clinical guidelines* |

2. Clinical practice

<table>
<thead>
<tr>
<th>Goals</th>
<th>Tools</th>
</tr>
</thead>
</table>
| Integrate geriatric evaluation (including comorbidities) into oncology decision-making and guidelines | • Comprehensive geriatric assessment  
• SIOG Clinical guidelines* |
| Improve the quality of prevention, diagnosis, treatment, and follow-up of older patients with malignancies | • SIOG Clinical guidelines* |
| Address issues of access to care, including the needs of the caregiver | • SIOG Clinical guidelines*  
• SIOG Task Forces active in various fields of geriatric oncology to produce position papers, consensus statements or clinical practice guidelines* |
| Develop interdisciplinary geriatric oncology clinics | • SIOG Clinical guidelines*  
• SIOG Task Forces active in various fields of geriatric oncology to produce position papers, consensus statements or clinical practice guidelines* |
3. Research

<table>
<thead>
<tr>
<th>Goals</th>
<th>Tools</th>
</tr>
</thead>
<tbody>
<tr>
<td>Develop, test and disseminate easy screening tools</td>
<td>• SIOG Geriatric Oncology Practice Centers Registry - research facilitating platform</td>
</tr>
<tr>
<td>Create a clear and operational definition of vulnerability/frailty applicable to oncology</td>
<td>• Geriatric Oncology grant for Young Researchers</td>
</tr>
<tr>
<td>Increase the relevance of clinical trials for older patients</td>
<td></td>
</tr>
<tr>
<td>Improve research in the field of geriatric oncology</td>
<td></td>
</tr>
<tr>
<td>Promote multidisciplinary, basic/translational research on the interface of aging and cancer</td>
<td></td>
</tr>
</tbody>
</table>

**SIOG Board members (2014-2016)**

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>President and Chair of SIOG Conference Committee</td>
<td>Etienne Brain</td>
<td>Institut Curie (Hôpital René Huguenin), St Cloud, France</td>
</tr>
<tr>
<td>President-Elect</td>
<td>Stuart Lichtman</td>
<td>Memorial-Sloan-Kettering Cancer Center, Commack, NY, United States</td>
</tr>
<tr>
<td>Immediate Past President</td>
<td>Arti Hurria</td>
<td>City of Hope Comprehensive Cancer Center, Duarte, CA, United States</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Hans Wildiers</td>
<td>UZ Leuven, Leuven, Belgium</td>
</tr>
<tr>
<td>Chair Corporate Relations Committee</td>
<td>Matti Aapro</td>
<td>Multidisciplinary Institute of Oncology, Genolier, Switzerland</td>
</tr>
<tr>
<td>Chair Fellowship, Nominating and Award Committee</td>
<td>Arti Hurria</td>
<td>City of Hope Comprehensive Cancer Center, Duarte, CA, United States</td>
</tr>
<tr>
<td>Chair Membership &amp; National Representatives Committee</td>
<td>Anita O'Donovan</td>
<td>Trinity College Dublin School of Medicine, Dublin, Ireland</td>
</tr>
<tr>
<td>Chair Publication Committee</td>
<td>Gouri Shankar Bhattacharyya</td>
<td>Fortis Hospital, Kolkata, India</td>
</tr>
<tr>
<td>Chair Science &amp; Education Committee</td>
<td>Tanya Wildes</td>
<td>Washington University School of Medicine, St. Louis, MO, United States</td>
</tr>
<tr>
<td>Chair Nursing &amp; Allied Health Interest Group</td>
<td>Cindy Kenis</td>
<td>UZ Leuven, Leuven, Belgium</td>
</tr>
<tr>
<td>Observer - Chair Young SIOG Interest Group</td>
<td>Nienke de Glas</td>
<td>Leiden University Medical Center, Leiden, Netherlands</td>
</tr>
<tr>
<td>Ex Officio - Chief Executive Officer</td>
<td>Laurence Verhagen</td>
<td>Geneva, Switzerland</td>
</tr>
</tbody>
</table>

**SIOG National Representatives**

The International Society of Geriatric Oncology (SIOG) National Representative is the bridge between the Society’s core and its members around the globe. As the Society’s spokespersons in their national respective countries, National and Regional Representatives act as ambassadors of SIOG’s mission, sharing the same values and pursuing the same objectives, in the joint effort to benefit the specialty of geriatric oncology on a national as well as international level.
SIOG Membership

SIOG members share a passion to implicate clinical practice in the elderly. Current SIOG membership comprises over 1130 individual members in 75 countries and continues to grow. Our current members are basic scientists, surgical oncologists, geriatricians, medical oncologists, radiation oncologists, psychologists, sociologists, nurses, nurse practitioners, and other healthcare professionals in active clinical practice interested in and/or involved in the management of older patients with cancer.

This year, SIOG wishes to acknowledge the membership anniversary of the following members who have been active within the society for 15, 10 and 5 years. SIOG thanks them for having contributed to the SIOG mission (improve cancer care for older adults), for having shown a continued commitment and for having supported our society for many years.

- Matti Aapro (EB)
- Riccardo Audisio (GB)
- Lodovico Balducci (US)
- Laura Biganzoli (IT)
- Harvey Jay Cohen (US)
- Jean Pierre Droz (FR)
- Martine Extermann (US)
- Arti Hurria (US)
- Jorge Oscar López (AR)
- Inmaculada Maestu (SP)
- Fausto Angelo Meriggi (IT)
- Silvio Monfardini (IT)
- Hyman Muss (US)
- Arash Naeim (US)
- Pol Specenier (BE)
- Christopher Steer (AU)
- Ulrich Wedding (DE)
- Hans Wildiers (BE)
- Gilbert Zulian (CH)

- Sandro Anchisi (CH)
- Bahram Forouzesh (AU)
- Anne Horgan (IE)
- Marit Slaaen Jordhøy (NO)
- Heidi Klepin (US)
- Hervé Le Caer (FR)
- Loretta Loftus (US)
- Oreste Mora (CH)
- Vicki Morrison (US)
- Francisco Luis Pimentel (PT)
- Martine Puts (CA)
- Carla Ripamonti (IT)
- Gideon Sunotoredjo (IDN)
- Barbara Van Leeuwen (NL)
- Manuela Zereu (BR)

- Maite Antonio Rebello (SP)
- Manon Chevalier (CA)
- Efrat Dotan (US)
- Tetsuya Hamaguchi (JP)
- Tina Hsu (CA)
- Joleen Hubbard (US)
- Heather Lane (AU)
- Ines Mattos (BR)
- Ruth Parks (GB)
- Jane Phillips (AU)
- Johanna Portielje (NL)
- Louisa Rattini-Reich (US)
- Mehmet Sonmez (FR)
- Deborah Standafer (US)
- Giampaolo Ugolini (IT)
- Soo Wee-Kheng (AU)
Membership benefits

- Access the Journal of Geriatric Oncology (JGO) - PubMed indexed - 6 ANNUAL ISSUES (in print + online or online only, depending on membership status)
- Access the Critical Reviews in Oncology/Hematology (CROH) - 12 ANNUAL ISSUES
- Get involved in SIOG educational activities, in the annual conference and governance
- Receive a discounted registration fee at SIOG Annual Conference
- Vote at the SIOG General Assembly and elect Board members
- Participate in Expert Task Forces
- Receive SIOG Newsletter
- Network with colleagues from all over the world and share your expertise
- Submit articles to the Journal of Geriatric Oncology (JGO), the only journal specifically dedicated to this area of medicine called geriatric oncology
- Benefit from reduced rates on some publications/books (e.g. ESMO Handbook of Geriatric Oncology, and other ESMO Handbooks)

In addition to the above mentioned benefits, members have the right to guide SIOG priorities and activities through voting at the General Assembly. The General Assembly is the supreme governing body of the society.

Join SIOG and help us achieve our goals!

With your help, SIOG will be able to:

- Improve the quality of prevention, diagnosis, treatment, and follow-up of older patients with malignancies
- Develop, test and disseminate easy screening tools.
- Increase public awareness of the worldwide cancer in the elderly epidemic

Become a member now!

More information at http://siog.org/content/join-siog

Final programme
What we do

Nursing & Allied Health Interest Group

The core responsibility of this interest group is to develop and promote, in accordance with the SIOG policies and strategy determined by the Board of Directors, excellence in geriatric oncology nursing through the SIOG strategic directions: education/clinical practice, research and advocacy. The N&AH interest group shall oversee the nursing and allied health related activities included in all SIOG scientific, educational and advocacy related projects.

Interest Group Leadership 2016 - 2018
Cindy Kenis (BE) - Chair
Petra Stolz Baskett (NZ) - Vice-Chair
Peggy Sue Burhenn (US)
Karis Cheng (SG)
Ginah Nightingale (US)
Martine Puts (CA)
Laurence Verhagen (CH), ex-officio

Nursing & Allied Health Interest Group activities during SIOG 2016

SIOG 2016 Nursing & Allied Health (NAH) meeting

Wednesday, November 16, 2016 - 14:00-16:45 - Club Bar (open to all registered delegates)
Chair: Cindy Kenis (BE)

14:00-14:10 Introduction
SIOG NAH Group

14:10-14:35 Polypharmacy practical aspects of clinical polypharmacy assessment and management
Ginah Nightingale (US)

14:35-15:00 Education of oncology nursing in geriatric oncology
Peggy Burhenn (US)

15:00-15:25 Patient engagement in research
Martine Puts (CA)

15:25-15:45 Break

15:45-16:40 Round table discussion based on group interest
All

16:40-16:45 Closing
SIOG NAH Group

SIOG 2016 Nursing & Allied Health Investigator Award

This award aims to recognise significant contributions from new investigators in geriatric oncology nursing and allied professions at international level. Selected for the outstanding quality of their work, two Nursing & Allied Professional Investigators will be competing for this SIOG Award. Finalists are: Martine Puts (CA) and Fay Strohschein (CA).

The SIOG 2016 Nursing & Allied Health Investigator award will be handed out during the SIOG Presidential session on Saturday, November 19, 2016 at 11:30 in Room Washington B.
Young SIOG Interest Group

Young SIOG is a SIOG Interest Group that was recently established by young clinicians and researchers, members of SIOG, who are working in the field of geriatric oncology. This interest group shall develop and promote in accordance with the SIOG policies and strategy determined by the Board of Directors, excellence in geriatric oncology nursing through the SIOG strategic directions: education/clinical practice, research and advocacy. The Young SIOG interest group shall oversee the young researchers in geriatric oncology related activities included in all SIOG scientific, educational and advocacy related projects.

Interest Group Leadership 2016 - 2018
Nienke de Glas (NL) - Chair
Nicolò Matteo Luca Battisti (IT & GB) - Vice-Chair
Capucine Baldini (FR)
Mandy Kiderlen (NL)
Melissa Loh (MY & US)
Manuel Rodrigues (FR)
Laurence Verhagen (CH), ex-officio

Young SIOG activities during SIOG 2016

SIOG 2016 Young SIOG mentorship session
Thursday, November 17, 2016 - 12:30-13:30 - Club Bar
Chairs: Nienke de Glas (NL) and Mandy Kiderlen (NL)
12:30-12:45 Difficulties in starting clinical studies in older patients
Tanya Wildes (US)
12:45-13:00 How to become a successful researcher in geriatric oncology
Pierre Soubeyran (FR)
13:00-13:15 Starting your career in geriatric oncology
Holly Holmes (US)
13:15-13:30 Why more oncologists do not embrace the concept of geriatric oncology and why more geriatricians miss the opportunities to connect with the oncologists
Armin Sharohkni (US)

Young SIOG Poster walk
Friday, November 18, 2016 - 10:30-11:00 - Poster area in room Washington A
Check out the best prospective and innovative studies for each of our five SIOG 2016 scientific tracks (P037, P042, P056, P073 and P093) led by Arti Hurria and Demetris Papamichael. Meeting point is the SIOG booth.

Young SIOG Plenary session
Saturday, November 19, 2016 - 12:30-13:30 - Washington B

The Young SIOG is a SIOG Interest Group that reaches out to all young clinicians and researchers who work in all disciplines that deal with cancer in older patients. In this plenary session of Young SIOG, ongoing and future projects of the group will be discussed. Members will get the opportunity to give feedback and to bring new ideas to the group.

SIOG 2016 Young Investigator Award
To promote research in the field of geriatric oncology and support the career development of the new generation of experts, SIOG will recognize three Young Investigators for their outstanding work. Award finalists are: Zachary Horne (US), Melissa Loh (US) and Suzanne Stokmans (NL).

The SIOG 2016 Young Investigator Awards will be handed out during the SIOG Presidential session on Saturday, November 19, 2016 at 11:30 in Room Washington B.
Scientific and educational projects

Taskforces
The International Society of Geriatric Oncology has as one of its major objectives to improve treatment and care for elderly patients with cancer. SIOG has developed a series of experts’ recommendations /guidelines published in international scientific journals (Lancet Oncology, Annals of Oncology, JCO, EJC, etc.) on the following topics. Please go to our website www.siog.org for full information.

The taskforces have several published documents that they produce:
- Peer-reviewed published articles with the official recommendations
- Newsletters about the meeting(s) preparing the recommendations
- Abstracts sent in to international conferences,
- Presentations in programs of scientific meetings
- Monographs with relevant educational topics

At the moment SIOG is preparing guidelines on the following topics:
- The use of radiopharmaceuticals in older patients with cancer (paper submitted for publication in the European Journal of Cancer)
- Chronic Lymphocytic Leukaemia in Older Patients (CLL) (paper accepted for publication in Annals of Oncology)
- Geriatric assessment in older cancer patients: SIOG standpoint
- Anti-HER2 targeted treatments in the Elderly with Breast Cancer (paper accepted for publication in Cancer Treatment Reviews)
- Bone protection in older patients with cancer
- Genomic prognosis and predictive tools for elderly cancer patients
- (The) management of elderly metastatic Renal Cell Carcinoma (mRCC) patients
- Anthracyclines in the elderly (Update)
- A Meta-analysis of cetuximab-based chemotherapy in the management of older patients with mCRC
- (The) treatment of bladder cancer in older cancer patients
- Prostate cancer in senior adults (Update)
- Adherence to oral cancer therapy for older patients

E-learning modules
The International Society of Geriatric Oncology, in a strategic partnership with ecancer, has collaborated to develop a series of online educational activities specifically addressing the special considerations that apply to managing the older patient with cancer. These free, continuing education activities aim to identify patient- and disease-related factors that may complicate treatment, and share expert perspectives about strategies and tools for providing optimal care for older patient with cancer. At the moment, three e-learning modules are available. Three more modules on Chronic Lymphocytic Leukaemia (CLL), oral chemotherapy and an update on prostate cancer will be launched soon. Check out our website www.siog.org for full details.

ESO / SIOG e-sessions
ESO in collaboration with SIOG has developed a webcast on Geriatric Oncology: a multidisciplinary approach in action. It was conducted by Etienne Brain (Hôpital René Huguenin / Institut Curie, Saint-Cloud, France) and Marije Hamaker (Diakonessenhuis Utrecht, Utrecht, The Netherlands). Another e-session is planned for Spring 2017 with the title: Geriatric Oncology: Why is it so important in our older breast cancer patient? Stay tuned and check out our website www.siog.org for more information.
**SIOG Advanced Course in Geriatric Oncology**

This course aims to train professionals in the management of elderly cancer patients, providing specific skills in assessment, care pathways and therapeutic choices about the elderly patients with cancer. The goal is to develop the general principles of both geriatric and oncology medicine that are useful to treat elderly cancer patients. The course is organised in conjunction with the Università Cattolica del Sacro Cuore. The next edition will be held in Summer 2017. More information is available on our website [www.siog.org](http://www.siog.org).

The 2016 Advanced Course in Geriatric Oncology successfully took place on June 28 to July 2, 2016 in Treviso, Italy and was attended by 33 students from all over the globe.

Come and check out our dedicated SIOG Advanced Course poster area in room Washington A where the 2016 course students have the possibility to showcase their planned projects following the course.

The following activities are organized as part of phase II of the SIOG 2016 Advanced Course in Geriatric Oncology:

- **Welcome coffee and follow up with course faculty and students**
  - Thursday, November 17, 2016, 10:30-11:00
  - Room: Gazebo (just behind the registration desk)
  - Meet up with your fellow students and the faculty to share feedback, expectations, improvements, unmet needs, etc.
  - Please note that this gathering is for the course students and faculty only.

- **Advanced Course Poster Walk**
  - Friday, November 18, 2016, 15:45-16:15
  - Room: Dedicated poster area in room Washington A
  - Course students will have the possibility to discuss their poster with the Geriatric Oncology community present at the conference and showcase planned projects after the course.

- **Final wrap up and knowledge assessment of the Advanced Course**
  - Saturday, November 19, 2016, 16:00-17:00
  - Room: Leonardo (on the first floor)
  - Multiple choice examination related to the SIOG 2016 Annual Conference plenary sessions, which will conclude the course and allow students to receive their final diploma.

**IMPORTANT:** This assessment is mandatory for all course students in order to obtain the final diploma and CME certificate of the Advanced Course.

Interested in attending the next edition of our SIOG Advanced Course? Please contact sabrina.marchal@siog.org to register your interest. Admission will open in January 2017.
General information

Conference venue
Milan Marriott Hotel
Via Washington, 66 - 20146 Milano, Italy
www.milanmarriotthotel.com

All scientific sessions will take place in the rooms Washington B and Club Bar. The poster and scientific displays as well as coffee breaks will take place in room Washington A; all rooms located on the ground floor of the hotel. Please refer to the venue floor plan on page 4 for more information.

Registration
The registration desk is located in the hotel lobby and will be open at the following hours:
- Wednesday, November 16 16:00-19:00*
- Thursday, November 17 07:30-19:45
- Friday, November 18 07:30-18:30
- Saturday, November 19 07:30-17:00
*The participants registered for the NAH meeting can collect their badge from 13:00 onwards.

Registration fee
The registration fee includes:
- Access to all scientific sessions
- Access to the posters and scientific display area
- Access to online abstract book (searchable pdf format) supplement of the Journal of Geriatric Oncology, which will be indexed and referenced in PubMed and Science Direct
- Access to conference proceedings after the conference
- Conference material
- Morning and afternoon coffee break
- Poster welcome reception on Thursday, Nov. 17 at 18:45
- WIFI connection for one device at the conference hotel for the duration of the conference (Nov. 17-19, 2016) – additional connections may be purchased at the reception desk of the hotel.
- 22% VAT (Value Added Tax)

Onsite registration
- SIOG Member EUR 725
- ESMO Member EUR 810
- Non-member EUR 945
- SIOG Member Trainee/Nurse/Patient Advocate EUR 420
- ESMO Member Trainee/Nurse/Patient Advocate EUR 545
- Non-member Trainee/Nurse/Patient Advocate EUR 680

Cash and credit card payments will be possible at the registration desk in Euro.

Name badges
All participants are requested to wear their name badges throughout the conference. If a badge is lost or forgotten, an administrative fee of EUR 80 will be charged for the reprint of the badge after identity verification (passport, driving license or other recognized identification document).

Certificate of attendance
Please complete the attendance form and bring it back to the registration desk starting Friday, November 18, 2016 as of 16:00. You will then receive your certificate.

Exhibition and scientific displays
Selected pharmaceutical and medical societies have been invited to exhibit their services. The exhibition is located in the room Washington A on the ground floor of the hotel.

Exhibition opening hours
- Thursday, November 17, 2016 10:30-19:45
- Friday, November 18, 2016 09:30-17:30
- Saturday, November 19, 2016 09:30-15:00

Speaker’s preview room opening hours
- Wednesday, November 16, 2016 16:30-18:30
- Thursday, November 17, 2016 07:30-19:45
- Friday, November 18, 2016 07:30-18:30
- Saturday, November 19, 2016 07:30-16:00

Scientific poster display
Posters will be displayed in the poster area during the whole duration of the conference within the exhibition area. Presenting authors are kindly requested to be present at their poster for presentation on:
- Thursday, November 17 10:30-11:00 / 12:30-13:30 / 16:00-16:30 and 18:45 for the Poster Welcome Reception
- Friday, November 18 10:30-11:00 / 12:00-13:00 and 15:45-16:15
- Saturday, November 19 10:00-10:30 and 12:30-13:30

Hanging: Thursday, November 12 08:30-12:30
Dismantling: Saturday, November 14 as of 16:00.
Posters not removed after 17:00 will be discarded.

eancer - expert interviews
Following last years success, eancer, the leading oncology channel, will again provide highlights of SIOG 2016 through scientific interviews of our conference experts. Stay tuned for when the interviews and webinars will be made available on SIOG and eancer websites.

This service is kindly supported by an unrestricted educational grant from MSD.
Poster welcome reception
Thursday, November 17 as of 18:45 within the poster area in room Washington A.
This scientific and networking event is offered by SIOG to allow all delegates and friends of SIOG to exchange best practices and facilitate collaborations.

Coffee break and lunch
All coffee breaks will be served in the room Washington A. If you have ordered lunch with your registration, you will receive vouchers for the corresponding days to access the lunch buffet, which is served in the “Salone Le Baron” between 12:00 and 13:30. Additional lunch vouchers can be purchased at the registration desk.

SIOG 2016 Networking dinner
The SIOG 2016 Networking dinner will take place at the Restaurant “El Brellin” in the romantic setting of Vicolo Lavandai, on Friday, November 18, 2016 at 19:30. The voucher for the dinner will be handed out with the delegate package for those who have ordered it. Additional vouchers can be purchased at the registration desk until maximum capacity is reached - do not miss out on what promises to be a fantastic evening once again. Full details regarding the venue are available on the voucher and the informational page included in your conference material. You will also find some information here below:
Scan the QR code with your smartphone or use the link to get the itinerary from the hotel
https://goo.gl/maps/NJgs4v3Mx22

Conference language
The official conference language is English. There will be no simultaneous translation available.

Messages
You may leave and collect messages at the registration desk.

WiFi
WiFi for one device per person is available throughout the conference venue free of charge for the duration of the Conference (Nov. 17-19). You will be handed out a WiFi code along with your badge at the registration desk. Once the code has been used on a device, it will no longer be active, and it will not be possible to use it on another device. Additional WiFi access codes may be purchased at the hotel reception desk.

Online abstract book
Delegates of the 2016 SIOG Annual Conference can enjoy complimentary full text access to the Journal of Geriatric Oncology from the first day of the conference, November 17 until December 2016. For your complimentary access, simply go to http://siog2016.elsevierdigitaledition.com

Onsite abstract printing
Printing of abstracts is possible at the Elsevier printing stand close to the registration area and session rooms.

Disclaimer
The conference organizers accept no liability for any injury or damage (including personal injury or for any loss, cost or damage to property belonging to conference participants) arising out of or in connection with the conference, including but not limited to during any activities. It is recommended that participants, as well as companies, arrange their own personal health, accident, travel, property loss/damage insurance or any other necessary insurance. MCI Suisse SA acts as agents and cannot be held responsible for any loss, cost, injury or damage to any person or property whatever the cause may be.
Defining Patient Management within SIOG Guidelines

Free, EACCME-accredited e-learning, to support your clinical development and improve geriatric cancer care

Topics include:
- Colorectal Cancer
- Radiopharmaceuticals
- Prostate Cancer

Coming soon:
- Oral Chemotherapy
- Chronic Lymphocytic Leukaemia

Start your learning journey at ecancer.org/education
Scientific programme committee

Ravindran Kanesvaran (SG) - Chair
Etienne Brain (FR) - Co-Chair
Laura Biganzoli (IT) - Local chair
Stefania Maggi (IT)
Matti Aapro (CH)
Laurence Verhagen (CH) - Ex officio

Track leaders and abstract reviewers

**Track 1: Solid tumours in the elderly and basic science**
Joleen Hubbard (US)
Gretchen Kimmick (US)
Olivier Michielin (CH)
Olivier Mir (FR)
Antonio Rossi (IT)
William Tew (US)
Rahul Unnikrishnan (IN)

**Track 2: Haem malignancies in the elderly and basic science**
Erel Joffe (IL)
Michele Spina (IT)
Reinhard Stauder (AT)
Tanya Wildes (US)

**Track 3: Supportive and palliative care**
Nicolò Matteo Luca Battisti (IT)
Alexandre Chan (SG)
William Dale (US)
Giovanni Gambassi (IT)
Jane Phillips (AU)
Fausto Rola (IT)
Christopher Steer (AU)

**Track 4: Modern diagnostics and therapeutic areas**
Massimo Di Maio (IT)
Clément Korenbaum (FR)
Laura Lozza (IT)
Christophe Massard (FR)
Giancarlo Pruneri (IT)
Rachel Richelmann (BR)
Giampaolo Ugolini (IT)

**Track 5: Geriatric assessment, nursing/allied health and socio-economic issues**
Karis Kin-Fong Cheng (SG)
Giuseppe Colloca (IT)
Theodora Karnakis (BR)
Alberto Pilotto (IT)
Rosanna Tarricone (IT)
Willemien van de Water (NL)
Faculty list

For full biographies of our SIOG 2016 please visit our website.

Matti Aapro (CH)
Luca Arcaini (IT)
Patrizio Armeni (IT)
Lodovico Baldacci (US)
Gouri Shankar Bhattacharyya (IN)
Laura Biganzoli (IT)
Paolo Bossi (IT)
Etienne Brain (FR)
Francesca Cerreta (BE)
Bruno Castagneto (IT)
Kwok-Leung Cheung (GB)
Raul Cordoba (SP)
Romain Corre (FR)
Andrea Costanzi (IT)
Nienke de Glas (NL)
Jean-Pierre Droz (FR)
Hassan Errihani (MO)
Abderrahim Fandi (FR)
Marilyn Filbet (FR)
Lucia Fratino (IT)
Tamas Fulop (CA)
Paolo Ghia (IT)
Marine Gilabert (FR)
Cesare Gridelli (IT)
Marij Henakker (NL)
Holly Holmes (US)
Arti Hurria (US)
Ravindran Kanesvaran (SG)
Joseph Kattan (LB)
Karlis Kin-Fong Cheng (SG)
Susan Knox (IT)
Ludmila Koch (BR)
Lalit Krishna (SG)
Marco Ladetto (IT)
Ian Kunkler (GB)
Alessandra Larocca (IT)
Trine Lembrecht Jørgensen (DK)
Stuart Lichtman (US)
Laura Lozza (IT)

Andrea Luciani (IT)
Stefania Maggi (IT)
Michele Malo (IT)
Christos Markopoulos (GR)
Christophe Massard (FR)
Francesco Merli (IT)
Stefania Migliuolo (IT)
Olivier Mir (FR)
Nicolas Mottet (FR)
Loic Mourey (FR)
Arash Naeim (US)
Anita O’Donovan (IE)
Rebecca Olin (US)
Nina Ommundsen (NO)
Roberto Orecchia (IT)
Cécile Ortholan (MC)
Demetris Papamichael (CY)
Heather Payne (GB)
Fausto Rola (IT)
Siri Rostoft (NO)
Patrick Roth (CH)
Florian Scotte (FR)
Ponnandai Somasundar (US)
Pierre Soubeyran (FR)
Reinhard Stauder (AT)
Kazuo Tamura (JP)
William Tew (US)
Clémence Thébaut (FR)
Janice Tsang (CN)
Giampaolo Ugolini (IT)
Willemien van de Water (NL)
Antonio Vigano (CA)
Ulrich Wedding (DE)
Tanya Wildes (US)
Hans Wildiers (BE)
Annie Young (GB)
Gilbert Zulian (CH)
CME accreditation

The SIOG 2016 Annual Conference has been granted 16 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation
European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.

Accreditation statement
Accreditation by the EACCME confers the right to place the following statement in all communication materials including the registration website, the event programme and the certificate of attendance. The following statements must be used without revision: “The 'International Society of Geriatric Oncology' (or) 'SIOG 2016 Annual Meeting' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net”

“The 'SIOG 2016 Annual Conference’ is designated for a maximum of (or ‘for up to’) 16 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Live educational activities, occurring outside of Canada, recognized by the UEMSEACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

The SIOG 2016 Scientific programme under the auspices, endorsed or recommended by:

In partnership with With the participation of
SIOG Awards

SIOG 2016 Nursing & Allied Health Investigator Award
This award aims to recognise significant contributions from new investigators in geriatric oncology nursing and allied professions at international level. Selected for the outstanding quality of their work, two Nursing & Allied Professional Investigators will be competing for this SIOG Award.

Meet our 2016 Award finalists:

MARTINE PUTS (CA)
Assistant professor tenure-stream, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto Canada

Martine has completed her Bachelor in Nursing, Master in Health Sciences and her PhD on the topic of Frailty in community-dwelling older adults in the Netherlands. She completed a postdoctoral fellowship with the Solidage Research Group on Frailty and Aging, Jewish General Hospital/Department of Biostatistics, Epidemiology and Occupational Health, McGill University, Montreal Canada. Her research focuses on improving care for frail older adults with cancer and she is particularly interested in geriatric assessment and management, treatment decision making and treatment adherence and quality of life. She has been awarded a Canadian Institutes of Health Research New Investigator Award to support her research.

Her abstract (O20) will be presented on Thursday, November 17, 2016 at 18:30 in room Washington B.

FAY STROHSCHEIN (CA)
Fay J. Strohschein, is a PhD candidate at the Ingram School of Nursing, McGill University, in Montreal, Canada. Her research interest in treatment decision making among older adults with cancer grew out of her clinical work with the Consultation Service for Senior Oncology Patients at the Jewish General Hospital, also in Montreal. She has worked as a Nursing Clinical Consultant/Nurse Navigator with this program since its inception in 2006. Throughout her studies, Fay has held fellowships with the Quebec Network for Research on Aging and the Psychosocial Oncology Research Training Program, funded by the Canadian Institutes of Health Research. Her dissertation study was funded through an Oncology Nursing Foundation (USA) Research Grant and a Fonds de recherché du Québec - Santé Doctoral Training Award.

Her abstract (O12) will be presented on Saturday, November 19, 2016 at 09:45 in room Washington B.

The SIOG 2016 Nursing & Allied Health Award will be handed out during the Presidential Session on Saturday, November 19 at 11:30 in room Washington B.
SIOG Awards (...continued)

SIOG 2016 Young Investigator Award

To promote research in the field of geriatric oncology and support the career development of the new generation of experts, the Young SIOG Investigator Award will recognize three young investigators for their outstanding work. Meet our 2016 Award finalists:

ZACHARY HORNE (US)
PGY-4, Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, US

Zachary D. Horne studied medicine at The George Washington University (United States) and received his medical degree in 2013. He is now a fourth year resident in Radiation Oncology at The University of Pittsburgh Cancer Institute. He anticipates a career in academic radiation oncology to continue pursuing research within the field with special attention to the geriatric population both in terms of patient outcomes and the cognitive/psychosocial effects of cancer and radiation therapy. His other research interests include the utilization of stereotactic ablative radiotherapy for early stage lung cancer and oligometastatic disease and the emotional/cognitive impacts of gynecologic brachytherapy.

His abstract (O02) will be presented on Saturday, November 19, 2016 at 09:15 in room Club Bar.

MELISSA LOH (US)

Melissa Loh is currently pursuing a fellowship in combined geriatrics and hematology/oncology at University of Rochester/Strong Memorial Hospital in the USA. She graduated from the Royal College of Surgeons in Ireland with dual degrees in Bachelor of Medical Science and Medicine. She then underwent her residency training at Baystate Medical Center/Tufts University School of Medicine. She is currently working with her mentor, Dr. Supriya Mohile in multiple geriatric oncology-related projects. She has experience in outcomes research, survey and retrospective studies. Her research interest includes sleep disturbance in older adults with cancer, cancer treatments and decision-making process, polypharmacy, antipsychotics use in the elderly, use of critical care therapies, use of information technology in cancer care coordination. She hopes to become a future clinician, researcher and educator.

Her abstract (O09) will be presented on Saturday, November 19, 2016 at 09:00 in room Washington B.

SUZANNE STOKMANS (NL)

Suzanne Stokmans (1988) is a Medical Doctor and first year PhD-student, currently working on her PhD thesis at the department of Surgical Oncology of the University Medical Center Groningen in the Netherlands. Her research is focused on biomarkers and functional status of onco-geriatric patients throughout the surgical treatment and is conducted under the supervision of Prof. dr. E. Heineman, Dr. B.L. van Leeuwen and Dr. J.J. de Haan. The results presented at this congress are part of a large single-center prospective observational cohort, the PICNIC trial, focusing on predicting postoperative outcome in elderly surgical cancer patients. In particular, the effects of the inflammatory response to a surgical procedure on postoperative cognitive decline are studied. The PICNIC research group is multidisciplinary; besides the department of Surgery, the department of Psychology, Anesthesiology, Medical Oncology and Epidemiology are involved as well.

Her abstract (O13) will be presented on Friday, November 18, 2016 at 11:00 in room Washington B.

The SIOG 2016 Young Investigator Award will be handed on during the Presidential Session on Saturday, November 19 at 11:30 in room Washington B.
SIOG 2016 Paul Calabresi Award
Every year, the International Society of Geriatric Oncology (SIOG) recognizes a prominent world expert in the Geriatric Oncology field by awarding them the Paul Calabresi Award. SIOG members have nominate a peer who has significantly contributed to the advancement of the geriatric oncology field over the past years through the publication of a high impact scientific paper, a significant influence on geriatric oncology policies, a major contribution in the advancement of international collaborations in the field or an outstanding and unconditional support to SIOG. The 2016 Paul Calabresi Award goes to Reinhard Stauder (AT).

REINHARD STAUDER (AT)
Associate Professor at the Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

Reinhard Stauder received his Doctoral Degree in Medicine in 1981 from the University of Innsbruck and in 2006 received a Master’s Degree in Health Sciences from the University of Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria. From 1994 - 1996, he was Scientific Member at the Basel Institute for Immunology, Basel, Switzerland.

Reinhard Stauder is a specialist in Internal Medicine, a Certified Specialist in Hematology and Oncology and Associate Professor of Medicine at Innsbruck Medical University, Austria. His main clinical and scientific focus lies in Myelodysplastic Syndromes (MDS), in geriatric oncology and in anemia in the elderly. His main goal is the development of individualized treatment algorithms in elderly cancer patients.

At present Reinhard Stauder is responsible for the geriatric oncology and MDS program of the Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University. Reinhard Stauder is a member of the European Leukemia Net (ELN) and is representative of Austria in the European LeukemiaNet MDS registry (EU-MDS). Reinhard Stauder is a member of the board of the Austrian Society for Haematology and Oncology and Associate Professor of Medicine at Innsbruck Medical University, Austria. His main clinical and scientific focus lies in Myelodysplastic Syndromes (MDS), in geriatric oncology and in anemia in the elderly. His main goal is the development of individualized treatment algorithms in elderly cancer patients.

The Paul Calabresi Award will be handed out during the Presidential Session on Saturday, November 19 at 11:30 in room Washington B.

SIOG 2016 National Representative of the year Award
The SIOG National Representative of the year Award recognizes the outstanding contribution to Geriatric Oncology and more particularly to SIOG for the past year. In 2016 Lore Decoster (BE) is awarded for her outstanding contribution.

LORE DECOSTER (BE)
Dr. Lore Decoster graduated from Medical School at the Vrije Universiteit Brussel (VUB), Brussels, Belgium in 2002. She subsequently started training in internal medicine during which she spent one year in different geriatric wards in Belgium. It was during this period that she became interested in older patients with cancer.

She received a recognition as medical oncologist in 2008 and since then she is a staff member at the oncology department at the University Hospital Brussel (UZ Brussel), Brussels, Belgium. Her main research interests are lung cancer, breast cancer, gynaecological cancers and geriatric oncology.

Since 2008 she has been focussing on geriatric oncology implementing geriatric assessment in daily practice at the UZ Brussel and performing research in older patients with cancer. Together with the teams from the UZ Leuven and the UCL, dr Decoster was a member of the scientific team coordinating the National Cancer Plan on geriatric oncology from 2011-2015. Her main goal currently is educating young medical oncologists and geriatricians in geriatric oncology.

Since 2014 Dr. Decoster is the National Representative for Belgium in SIOG.

The SIOG 2016 National Representative of the year Award will be handed out during the SIOG General Assembly on Friday, November 18 at 12:00 in room Club Bar.
Pre-conference - Wednesday, November 16, 2016

Club Bar

14:00-16:45  SIOG 2015 Nursing and Allied Health (NAH) meeting  Chair: Cindy Kenis (BE)
14:00-14:10  Introduction  SIOG NAH Group
14:10-14:35  Polypharmacy practical aspects of clinical polypharmacy assessment and management  Gineh Nightingale (US)
14:35-15:00  Education of oncology nursing in geriatric care  Peggy Burhenn (US)
15:00-15:25  Patient engagement in research  Martine Puts (CA)

15:25-15:45  Break
15:45-16:40  Round table discussion based on group interest  All
16:40-16:45  Closing  SIOG NAH Group

DAY 1 - Thursday, November 17, 2016

Washington B

08:30-09:00  Opening address
08:30-08:40  Opening address by SIOG President  Etienne Brain (FR)
08:40-08:45  Scientific programme overview by the Chair of SIOG 2016 Annual Conference  Ravindran Kanesvaran (SG)
08:45-08:50  Welcome address by National Host  Laura Biganzoli (IT)
08:50-09:00  Musical interlude

09:00-10:30  Plenary session: Advancements in the field of geriatric oncology  Chairs: Etienne Brain (FR) and Stuart Lichtman (US)
09:00-09:20  Updates in surgery  Ponnandai Somasundar (US)
09:20-09:40  Updates in geriatrics  Stefania Maggi (IT)
09:40-10:00  Updates in medical oncology  Loic Mourey (FR)
10:00-10:20  Updates in radiotherapy  Laura Lozza (IT)
10:20-10:30  Discussion and questions

10:30-11:00  Coffee break - Poster viewing

Washington B

11:00-12:30  Industry sponsored satellite session
Please see page 40 for further information

12:30-13:30  Lunch break - Poster viewing and exhibition

Club Bar

12:30-13:30  Young SIOG mentorship session  Chairs: Nienieke de Glas (NL) and Mandy Kiderlen (NL)
12:30-12:45  Difficulties in starting clinical studies in older patients  Tanya Wildes (US)
12:45-13:00  How to become a successful researcher in geriatric oncology  Pierre Soubeyran (FR)
13:00-13:15  Starting your career in geriatric oncology  Holly Holmes (US)
13:15-13:30  Why more oncologists do not embrace the concept of geriatric oncology  Armin Sharohkni (US)
and why more geriatricians miss the opportunities to connect with the oncologists

Washington B

13:30-14:45  Poor prognostic tumours in the elderly: where do we stand?  Chairs: Lucia Fratino (IT) and Romain Corre (FR)
13:45-14:00  CGA in advanced lung cancer: what have we learned and what is next?  Andrea Luciani (IT)
14:00-14:15  Are glioblastoma well treated in the elderly?  Patrick Roth (CH)
14:15-14:30  Systemic treatments to elderly sarcoma patients: Doxorubicin and beyond  Olivier Mir (FR)
14:30-14:45  Discussion and questions
DAY 1 - Thursday, November 17, 2016

Club Bar

Chairs: Pierre Soubeyran (FR) and Raul Cordoba (SP)

13:30-13:45 Follicular NHL in the elderly: role of geriatric assessment and therapy  
Marco Ladetto (IT)

13:45-14:00 Mantle Cell NHL: utilization of older and newer agents in the elderly patient  
Pierre Soubeyran (FR)

14:00-14:15 Marginal zone and lymphoplasmacytic NHL: less common, though still important, variants in the elderly patient  
Luca Arcaini (IT)

14:15-14:30 Who is fit for haematological stem cell transplantation?  
Reinhard Stauder (AT)

Washington B

15:00-16:00 Debate session: Clinical research in geriatric oncology: adaptation or revolution?  
Facilitator: Etienne Brain (FR)

The following key issues will be debated:
- Differences between elderly patients included in clinical trials and real world populations  
Arti Hurria (US)
- Endpoints and design in clinical trials  
Matti Aapro (CH)
- Challenges around real life data  
Siri Rostoft (NO)
- Perspectives of an oncologist  
Susan Knox (IT)
- Perspectives of a supportive care specialist  
Patrizio Armeni (IT)
- Perspectives from a geriatrician  
Pasquale Leone (IT)
- Perspectives from a patient advocate  
Via video streaming - Francesca Cerreta (BE)
- Perspectives from a healthcare economist  
Abderrahim Fandi (FR)

16:00-16:30 Coffee break - Poster viewing and exhibition

Washington B

16:30-17:45 Quality of life in geriatric population: why, what and how?  
Chairs: Florian Scotté (FR) and Siri Rostoft (NO)

16:30-16:43 Daily living with cancer: the patient's voice  
Susan Knox (IT)

16:43-16:56 Are patient reported outcomes programmes adapted to the geriatric population?  
Paolo Bossi (IT)

16:56-17:09 Are tools the right way to assess quality of life in elderly?  
Ulrich Weddinger (DE)

17:09-17:21 Quality of life management: yes, we need guidelines!  
Florian Scotté (FR)

17:21-17:45 Debate amongst speakers and audience

Club Bar

16:30-17:45 Making strides in local strategies for elderly patients  
Chairs: Ponnandai Somasundar (US) and Cécile Ortholan (MC)

16:30-16:45 Prehabilitation before surgery  
Nina Ommundsen (NO)

16:45-17:00 Minimizing perioperative adverse events in the elderly  
Giampaolo Ugliolini (IT)

17:00-17:15 Stereotactic and other promising advanced radiation techniques in elderly  
Cécile Ortholan (MC)

17:15-17:30 The impact of radiation toxicity on quality of life of older patients  
Anita O'Donovan (IE)

17:30-17:45 Discussion and questions

Washington B

17:45-18:30 Oral abstract session: Geriatric assessment, nursing/allied health & socio-economic issues  
Chairs: Karis Kin-Fong Cheng (SG) and Nienke de Glas (NL)

17:45-18:00 O17 - Frailty and systemic inflammation-based Glasgow prognostic score  
Magnus Harneshaug (NO)

18:00-18:15 O18 - A clinical score to predict the early death at 100 days after a comprehensive geriatric assessment (CGA) in elderly metastatic cancers, analysis from a prospective cohort study with 1048 patients  
Rabia Boulaaiss (FR)

18:15-18:30 O19 - An observational study of the interventions provided by a multidisciplinary team providing comprehensive geriatric assessment to older adults with upper gastro-intestinal cancers  
Anne Sims (GB)

18:30-18:45 O20 - A feasibility trial of geriatric assessment and integrated care plan for older cancer patients  
Martine Puts (CA) - SIOG 2016 NAH Award Finalist

Final programme
DAY 1 - Thursday, November 17, 2016

Club Bar

17:45-18:45 Debate - End-of-life issues: respecting the patient’s dignity around the world
Chairs: Gilbert Zulian (CH) and Holly Holmes (US)

17:45-18:00 Perspectives from Europe
Marilène Filbet (FR)

18:00-18:15 Perspectives from North America
Holly Holmes (US)

18:15-18:30 Perspectives from Asia
Lalit Krishna (SG)

18:30-18:45 Summary by the chairs
Gilbert Zulian (CH) and Holly Holmes (US)

Washington A

18:45-19:45 Poster welcome reception
DAY 2 - Friday, November 18, 2016

Washington B  
08:00-09:30  Plenary session: Geriatric oncology: multidisciplinary approach in a global environment  
Chairs: Ravindran Kanesvaran (SG) and Laura Biganzoli (IT)  

08:00-08:13  North America  
Arti Hurria (US)  
08:13-08:26  Europe  
Pierre Soubeyran (FR)  
08:26-08:39  Japan  
Kazuo Tamura (JP)  
08:39-08:52  China  
Janice Tsang (CN)  
08:52-09:05  Middle East  
Joseph Kattan (LB)  
09:05-09:18  Latin America  
Ludmila Koch (BR)  
09:18-09:30  Discussion and questions  

Washington B  
09:30-10:30  Resource stratified geriatric oncology practice: a global view  
Chairs: Willemien van de Water (NL) and Karis Kin-Fong Chen (SG)  

09:30-09:42  Geriatric oncology practice in tropical area: experience in French Guiana  
Jean-Pierre Droz (FR)  
09:42-09:54  Cancer in Moroccan elderly: the first multicentric transversal study exploring the socio-demographic and economic profile of Moroccan elderly cancer patients  
Hassan Errhani (MO)  
09:54-10:06  Geriatric oncology: the view from Latin America  
Ludmila Koch (BR)  
10:06-10:18  Geriatric assessment, nursing/allied health & socio-economic issues in China  
Janice Tsang (CN)  
10:18-10:30  Discussion and questions  

Club Bar  
09:30-10:30  Oral abstract session: Haem malignancies in the elderly and basic science  
Chairs: Tamas Fulop (CA) and Raul Cordoba (SP)  

09:30-09:45  O05 - Transcription factors and checkpoint inhibitor expression with age: new markers of immunosenescence?  
Dominique Bron (BE)  
09:45-10:00  O06 - Ofatumumab as front-line treatment for patients with chronic lymphocytic leukaemia that are elderly and have severe co-morbidities and/or other malignancies  
Alessandra Ferrajoli (US)  
10:00-10:15  O07 - What evidence do we have for treating relapsed/refractory AML in patients 70 and older? A systematic review of the literature  
Martine Extermann (US)  
10:15-10:30  O08 - Early case management in the older French haematological malignancies patient receiving chemotherapy, preliminary results  
Jean-Baptiste Fargeas (FR)  

10:30-11:00  Coffee break - Poster viewing and exhibition  

10:30-11:00  Young SIOG poster walk  
Chairs: Arti Hurria (US) and Demetris Papamichael (CY)  
Meeting point: SIOG booth.  

Washington B  
11:00-12:00  Oral abstract session: Modern diagnostics and therapeutic areas  
Chairs: Hans Wildiers (BE) and Stuart Lichtman (US)  

11:00-11:15  O13 - Long term outcome in elderly surgical cancer patients  
Suzanne Stokmans (NL) - Young SIOG Investigator Award 2016 finalist  
11:15-11:30  O14 - Inclusion of elderly patients in oncology clinical trials  
Olivia Le Saux (FR)  
11:30-11:45  O15 - Large outcome disparities by older age and 21-gene recurrence score (RS) result in hormone receptor positive (HR+) breast cancer (BC)  
Steven Shak (US)  
11:45-12:00  O16 - Primary endpoints to assess treatment efficacy in clinical trials conducted in elderly cancer patients  
Fanny Etchpare (FR)  

Club Bar  
11:00-12:00  Clinical trials in geriatric oncology: learning from the past to build on the future  
Chairs: Arti Hurria (US) and Joseph Kattan (LB)  

11:00-11:12  Overview and perspectives  
Ravindran Kanesvaran (SG)  
11:12-11:24  Challenges and opportunities  
Willemien van de Water (NL)  
11:24-11:36  End points, quality vs. quantity of data  
Pierre Soubeyran (FR)  
11:36-11:48  Comprehensive geriatric assessment as stratification tool in elderly patients with haematological malignancies  
Francesco Merli (IT)  
11:48-12:00  Discussion and questions  

- SIOG sessions  - Plenary sessions  - Track 1  - Track 2  - Track 3  - Track 4  - Track 5  - Industry sponsored satellite sessions
### DAY 2 - Friday, November 18, 2016

**12:00-13:30**  
**Lunch break - Poster viewing and exhibition**  

**Club Bar**

**12:00-13:00**  
**SIOG General assembly**

**Washington B**

**13:00-14:00**  
**SIOG/EUSOMA Round table discussion:**  
*Treatment of early breast cancer in the elderly: from evidence to clinical practice*  
Facilitator: Hans Wildiers (BE)

- SIOG: Etienne Brain (FR), Kwok-Leung Cheung (GB), Marije Hamaker (NL) and Ian Kunkler (GB)
- EUSOMA: Laura Biganzoli (IT), Christos Markopoulos (GR) and Roberto Orecchia (IT)

- **13:00-13:20**  
The treatment of the axilla in clinically node negative disease

- **13:20-13:40**  
The role of radiotherapy after conservative surgery in low-risk patients

- **13:40-14:00**  
Adjuvant chemotherapy: the right treatment for the right patient

**Club Bar**

**13:00-14:00**  
**Is less as good as more in some haematological malignancies?**  
*Chairs: Tanya Wildes (US) and Reinhard Stauder (AT)*

- **13:00-13:15**  
Multiple myeloma in the elderly  
Tanya Wildes (US)

- **13:15-13:30**  
Treatment of elderly patients with AML  
Rebecca Olin (US)

- **13:30-13:45**  
Chemofree follicular lymphoma  
Raul Cordoba (SP)

- **13:45-14:00**  
Discussion and questions

**Washington B**

**14:15-15:45**  
**Geriatric assessment to stratify treatment of older cancer patients**  
*Chairs: Arti Hurria (US) and Alessandra Larocca (IT)*

- **14:15-14:33**  
Prostate cancer  
Heather Payne (GB)

- **14:33-14:51**  
CLL  
Paolo Ghia (IT)

- **14:51-15:09**  
Multiple myeloma  
Alessandra Larocca (IT)

- **15:09-15:27**  
Haematology  
Reinhard Stauder (AT)

- **15:27-15:45**  
Discussion and questions

**15:45-16:15**  
**Coffee break - Poster viewing and exhibition**

**Washington B**

**16:15-17:15**  
**Special partnership session: SIOG & GIOGer**  
*Geriatric oncology in Italy: the GIOGer experience*  
*Chairs: Bruno Castagneto (IT) and Etienne Brain (FR)*

- **16:15-16:27**  
Introduction: report from the Italian network  
Bruno Castagneto (IT)

- **16:27-16:39**  
Organisation models of the clinical activity at the GIOGer Centres  
Lucia Fratino (IT)

- **16:39-16:51**  
The European and global dimension in geriatric oncology  
Etienne Brain (FR)

- **16:51-17:03**  
Future strategies and collaborations  
Andrea Luciani (IT)

- **17:03-17:15**  
Discussion and questions

**Washington B**

**17:15-18:30**  
**What is new in the GI and gynaecological tumours in the elderly?**  
*Chairs: Demetris Papamichael (CY) and William Tew (US)*

- **17:15-17:27**  
Gynaecological cancers  
William Tew (US)

- **17:27-17:39**  
Pancreatic cancers  
Marine Gilabert (FR)

- **17:39-17:51**  
Special considerations with regard to colorectal surgery in the elderly  
Andrea Costanzi (IT)

- **17:51-18:03**  
Colorectal cancer  
Demetris Papamichael (CY)

- **18:03-18:15**  
Genitourinary tumours in the elderly patients  
Lucia Fratino (IT)

- **18:15-18:30**  
Discussion and questions

**Club Bar**

**17:15-18:30**  
**SIOG & MASCC joint session: Supportive care in geriatric oncology**  
*Chairs: Fausto Roila (IT) and Florian Scotté (FR)*

- **17:15-17:27**  
Studying supportive care in a new geriatric oncology programme in Denmark  
Trine Lembrecht Jørgensen (DK)

- **17:27-17:39**  
Co-ordinating supportive care between hospital and home  
Florian Scotté (FR)

- **17:39-17:51**  
Improving nutrition status sooner rather than later  
Antonio Vigano (CA)

- **17:51-18:03**  
Issues on pain management in elderly  
Laith Krishna (SG)

- **18:03-18:15**  
MASCC guidelines in fatigue adapted to geriatric oncology  
Fausto Roila (IT)

- **18:15-18:30**  
Discussion and questions
# DAY 3 - Saturday, November 19, 2016

**Washington B**

### 08:00-09:30 Plenary session: Hot topics in geriatric oncology  
**Chairs:** Ravindran Kanesvaran (SG) and Tanya Wildes (US)

- **08:00-08:12** Quality of life  
  - Stefania Migliuolo (IT)
- **08:12-08:24** Health economics  
  - Clémence Thébaut (FR)
- **08:24-08:36** Immunotherapy  
  - Christophe Massard (FR)
- **08:36-08:48** Geriatric assessment: next big challenges  
  - Marije Hamaker (NL)
- **08:48-09:00** Discussion and questions

### 09:00-10:00 Oral abstract session: Supportive and palliative care  
**Chairs:** Holly Holmes (US) and Anita O’Donovan (IE)

- **09:00-09:15** O09 - Depression is associated with sleep disturbance in older adults with cancer  
  - Melissa Loh (US) - SIOG 2016 Young Investigator Finalist
- **09:15-09:30** O10 - A phase II RCT of three exercise delivery methods in older men with prostate cancer on androgen deprivation therapy  
  - Shabbir Alibhai (CA)
- **09:30-09:45** O11 - Prevalence and factors associated with high level of distress among older cancer patients undergoing surgery  
  - Armin Shahrokni (US)
- **09:45-10:00** O12 - Choosing to trust: cancer treatment decision making from the perspective of older adults with colorectal cancer  
  - Fay Strohschein (CA) - SIOG 2016 NAH Award Finalist

### Club Bar

### 09:00-10:00 Oral abstract session: Solid tumours in the elderly and basic science  
**Chairs:** Kwok-Leung Cheung (GB) and Lodovico Balducci (US)

- **09:00-09:15** O01 - Relevance of geriatric assessment in older patients with colorectal cancer  
  - Lore Decoster (BE)
- **09:15-09:30** O02 - National patterns of care and outcomes of oropharyngeal squamous cell carcinomas in patients over 70  
  - Zachary Horne (US) - SIOG 2016 Young Investigator Finalist
- **09:30-09:45** O03 - Geriatric assessment and outcomes with carboplatin and weekly low-dose Paclitaxel in elderly women with ovarian, primary peritoneal or fallopian tube cancer: a gynaecologic oncology group study (GOG273)  
  - William Tew (US)
- **09:45-10:00** O04 - Taxane-based adjuvant treatment in elderly women with breast cancer. A pooled analysis of 5 randomized trials from the Hellenic oncology research group  
  - Athanasios Karampeazis (GR)

### 10:00-10:30 Coffee break - Poster viewing and exhibition

### Washington B

### 10:30-11:30 Industry sponsored satellite session

*Please see page 40 for further information*

### Washington B

### 11:30-12:30 SIOG presidential session and SIOG 2016 awards  
**Chair:** Etienne Brain (FR)

- **11:30-11:40** Presidential address  
  - Stuart Lichtman (US)
- **11:40-11:50** Calabresi award  
  - Reinhard Stauder (AT)
- **11:50-12:00** SIOG 2016 Nursing & Allied Health investigator award  
  - Etienne Brain (FR) and Stuart Lichtman (US)
- **12:00-12:10** SIOG 2016 Young Investigator award  
  - Etienne Brain (FR) and Stuart Lichtman (US)
- **12:10-12:20** SIOG 2016 Best Poster award  
  - Etienne Brain (FR) and Stuart Lichtman (US)
- **12:20-12:30** SIOG 2017 Annual Conference announcement  
  - Stuart Lichtman (US)

### Washington B

### 12:30-13:30 Young SIOG Plenary session  
**Chair:** Nienke de Glas (NL)

The Young SIOG is a SIOG Interest Group that reaches out to all young clinicians and researchers who work in all disciplines that deal with cancer in older patients. In this plenary session of Young SIOG, ongoing and future projects of the group will be discussed. Members will get the opportunity to give feedback and to bring new ideas to the group.

### Club Bar

### 12:30-13:30 SIOG Membership and National Representative Committee meeting
DAY 3 - Saturday, November 19, 2016

12:30-13:30  Lunch break - Poster viewing and exhibition

Washington B
13:30-14:45  Immunotherapy for elderly cancer patients  
Chairs: Stuart Lichtman (US) and Cesare Gridelli (IT)
13:30-13:45  Is immunity compromised in the elderly and does this impact on cancer immunotherapy?  
Tamas Fulop (CA)
13:45-14:00  Do agents used in immunotherapy share a common mechanism of action and how to predict efficacy?  
Christophe Massard (FR)
14:00-14:15  Lung cancer in the elderly patients  
Cesare Gridelli (IT)
14:15-14:30  Melanoma in the elderly patients  
Michele Maio (IT)
14:30-14:45  Discussion and questions

Club Bar
13:30-14:45  Monitoring geriatric oncology patients  
Chairs: Arash Naeim (US) and Stefania Maggi (IT)
13:30-13:45  Wearable and home sensors  
Arash Naeim (US)
13:45-14:00  Mobile apps and smartphones  
Annie Young (GB)
14:00-14:15  Cognitive dysfunction: why does it matter in older patients with cancer?  
Siri Rostoft (NO)
14:15-14:30  Generating evidence about effectiveness and value  
Gouri Shankar Bhattacharyya (IN)
14:30-14:45  Discussion and questions

Washington B
14:45-15:45  SIOG Guidelines update 2016  
Chairs: Gouri Shankar Bhattacharyya (IN) and Tanya Wildes (US)
14:45-14:57  The management of prostate cancer in senior adults  
Jean-Pierre Droz (FR)
14:57-15:09  The treatment of bladder cancer in older cancer patients  
Nicolas Mottet (FR)
15:09-15:21  The management of elderly metastatic Renal Cell Carcinoma patients  
Ravindran Kanesvaran (SG)
15:21-15:33  The appropriate targeted anti-HER 2 treatment strategy for elderly patients with breast cancer  
Etienne Brain (FR)
15:33-15:45  Discussion and questions
**Scientific poster display**

Abstract posters will be displayed in the poster area within the exhibition area during the whole duration of the conference. Presenting authors are kindly requested to be present at their poster for presentation on:

- **Thursday, November 17, 2016**
  - 10:30-11:00 / 12:30-13:30 / 16:00-16:30
  - and 18:45 for the Poster Welcome Reception
- **Friday, November 18, 2016**
  - 10:30-11:00 / 12:00-13:00 and 15:45-16:15
- **Saturday, November 19, 2016**
  - 10:00-10:30 and 12:30-13:30

**New this year: Young SIOG Poster walk**

Friday, November 18, 2016 - 10:30-11:00 - Poster area in room Washington A

Check out the best prospective and innovative studies for each of our five SIOG 2016 scientific tracks (P037, P042, P056, P073 and P093 - highlighted with the Young SIOG Logo on the following poster listing) led by Arri Hurria and Demetris Papamichael.

Meeting point for the poster walk is the SIOG booth.

---

<table>
<thead>
<tr>
<th>TRACK 1: SOLID TUMOURS IN THE ELDERLY AND BASIC SCIENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abstract final identifier</strong></td>
</tr>
<tr>
<td>------------------------------</td>
</tr>
<tr>
<td>P001</td>
</tr>
<tr>
<td>P002</td>
</tr>
<tr>
<td>P003</td>
</tr>
<tr>
<td>P004</td>
</tr>
<tr>
<td>P005</td>
</tr>
<tr>
<td>P007</td>
</tr>
<tr>
<td>P008</td>
</tr>
<tr>
<td>P009</td>
</tr>
<tr>
<td>P010</td>
</tr>
<tr>
<td>P011</td>
</tr>
<tr>
<td>P012</td>
</tr>
<tr>
<td>P013</td>
</tr>
<tr>
<td>P014</td>
</tr>
<tr>
<td>P015</td>
</tr>
<tr>
<td>P016</td>
</tr>
<tr>
<td>P017</td>
</tr>
</tbody>
</table>
Final programme
16th Conference of the International Society of Geriatric Oncology
“Geriatric oncology: a multidisciplinary approach in a global environment”

P018 Jens Benn Sørensen
OCTOGENARIANS WITH INOPERABLE MALIGNANT PLEURAL MESOTHELIOMA: OUTCOME OF CARBOPLATIN AND Pemetrexed chemotherapy, A SIX YEARS CONSECUTIVE COHORT.

P020 Karlijn Schulkes
MULTIDISCIPLINARY DECISION-MAKING IN LUNG CANCER PATIENTS: AN AGED BASED COMPARISON

P021 Katieen Fagard
POSTOPERATIVE COMPLICATIONS AND MORTALITY IN INDIVIDUALS AGED 70 AND OLDER UNDERGOING SURGERY FOR colorectal cancer.

P022 Laure Pierard
EFFICACY AND SAFETY OF ANTIANGIOGENIC THERAPIES IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL Carcinoma: A RETROSPECTIVE MULTICENTER STUDY

P023 Leila Bengrine Lefeuvre
TOLERANCE AND EFFICACY OF FOLFIRINOX IN ELDERLY PATIENTS WITH PANCREATIC OR colorectal CANCER. A MONOCEFENTRIC RETROSPECTIVE STUDY ON 52 PATIENTS.

P024 Lore Decoster
GERIATRIC ASSESSMENT AND FUNCTIONAL DECLINE IN OLDER PATIENTS WITH LUNG CANCER.

P025 Maria Teresa Antonio Rebollo
UTILITY OF GERIATRIC ASSESSMENT IN ELDERLY PATIENTS WITH LOCALLY ADVANCED LUNG CANCER TO BE TREATED WITH CONCURRENT CHEMOREAIMATION

P026 Kwok-Leung Cheung
CLUSTERING ANALYSIS OF OESTROGEN RECEPTOR POSITIVE EARLY OPERABLE PRIMARY BREAST CANCER IN OLDER WOMEN – A STUDY BASED ON CORE NEEDLE BIOPSY

P027 Loïc Mourey
FINAL RESULTS OF GERICO 10 GETUG P03 TRIAL EVALUATING FEASIBILITY OF DOCEXATEL IN VULNERABLE OR FRAIL ELDERLY (75+) PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER

P028 Myriam Langlois
UNRESECTABLE AND METASTATIC PANCREATIC ADENOCARCINOMA IN THE ELDERLY: A 10-YEAR SINGLE-CENTER EXPERIENCE

P029 Marijke Hamaker
THE IMPACT OF AN OSTOMY ON OLDER COLORECTAL CANCER PATIENTS: A CROSS-SECTIONAL SURVEY

P030 Ponnandai Somasundar
HCC ASSOCIATED WITH HIGHEST INPATIENT POST-OPERATIVE MORTALITY AMONGST GI CANCERS: ELDERLY AGE HIGHEST PREDICTIVE RISK FACTOR

P031 Rahul Unnikrishnan
RETROSPECTIVE CORELATION OF BIOPSY WITH PSA SCREENING VALUES OF GERIATRIC INDIVIDUALS IN A TERTIARY CARE HOSPITAL IN INDIA

P032 Regina Gironès
A PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB WITH CYTOXIC CHEMOTHERAPY: AS FIRST LINE TREATMENT, IN OLDER PATIENTS WITH ADVANCED/METASTATIC NSCLC (NON-SQUAMOUS) SELECTED BY A GERIATRIC ASSESSMENT: GIDO1201

P033 Regina Gironès
ARE OLDER PATIENTS PROPERLY REPRESENTED IN CLINICAL TRIALS? ANALYSIS OF THE SCREENING FAILURES REASONS IN ELDERLY NON-SMALL CELL LUNG CANCER PATIENTS (NSCLC) STAGE IV ASSESSED FOR BEVACIZUMAB THERAPY (GIDO1201 TRIAL)

P034 Ruth Mary Parks
SHORT-TERM CHANGES IN MOOD AS MEASURED BY COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) SCORES FOLLOWING TREATMENT OF PRIMARY BREAST CANCER IN OLDER WOMEN

P035 Shabbir MH Alibhai
ANDROGEN DEPRIVATION THERAPY AND THE RISK OF PARKINSONISM IN OLDER MEN WITH PROSTATE CANCER

P036 Sharon E Robertson
CLINICAL AND TREATMENT FACTORS ASSOCIATED WITH SURVIVAL AMONG WOMEN 70 YEARS AND OLDER WITH EPITHELIAL OVARIAN CANCER

P037 Vasiliki Michalaki
SAFETY AND EFFICACY OF LOWER DOSE WEEKLY TOPOTECAN IN ELDERLY PATIENTS WITH PLATINUM RESISTANT OVARIAN AND PERITONEAL CANCER

P038 Riccardo Audisio
DO WE KNOW WHAT OLDER WOMEN WITH BREAST CANCER WANT? DECISION MAKING PREFERENCES FOR TYPE OF TREATMENT, FOLLOW UP AND PERCEPTIONS OF COSMETIC OUTCOMES

P039 Yuan Yuan
ASSOCIATION OF PRE-CHEMOTHERAPY PERIPHERAL BLOOD BIOMARKERS OF AGING (IL-6, CRP AND D-DIMER) WITH CHEMOTHERAPY TOXICITY AND RELATIVE DOSE INTENSITY (RDI) IN WOMEN WITH BREAST CANCER

P143 Karis King-Fong Cheng
FUNCTIONAL STATUS, QUALITY OF LIFE AND UNMET NEEDS IN OLDER PATIENTS WITH LUNG CANCER

---

**TRACK 2: HAEM MALIGNANCIES IN THE ELDERLY AND BASIC SCIENCE**

<table>
<thead>
<tr>
<th>Abstract final identifier</th>
<th>Presenting author</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P040</td>
<td>Raul Cordoba</td>
<td>DIFFUSE LARGE B CELL LYMPHOMA: AN OVERVIEW OF THE DISEASE WITH SPECIAL FOCUS ON CIRS SCALE AND EMERGENCY VISITS IN THE ELDERLY POPULATION.</td>
</tr>
<tr>
<td>P041</td>
<td>Masaru Shibata</td>
<td>COMPREHENSIVE GERIATRIC ASSESSMENT MAY BE USEFUL AS PREDICTIVE INDEX OF TREATMENT COMPLETION FOR ELDERLY PATIENTS WITH LYMPHOMA.</td>
</tr>
<tr>
<td>P042</td>
<td>Natacha Carmel</td>
<td>SEGA (SHORT EMERGENCY GERIATRIC ASSESSMENT) FRAILTY SCORE IN ELDERLY PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES</td>
</tr>
<tr>
<td>P043</td>
<td>Dominique Bron</td>
<td>A NEW FRAILTY SCORING IN “CLINICALLY FIT” OLDER PATIENTS WITH MALIGNANT HEMOPATHIES ADMITTED TO RECEIVE CHEMOTHERAPY</td>
</tr>
<tr>
<td>P044</td>
<td>Vipin Lohiya</td>
<td>EFFECT OF ADEQUATE HYPMETHYLATING AGENT (HMA) THERAPY ON ADVERSE PROGNOSTIC FACTORS IN VERY ELDERLY PATIENTS (&gt;75 YRS) WITH MYELODYSPLASTIC SYNDROME (MDS).</td>
</tr>
</tbody>
</table>
## TRACK 3: SUPPORTIVE AND PALLIATIVE CARE

<table>
<thead>
<tr>
<th>Abstract final identifier</th>
<th>Presenting author</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P045</td>
<td>Armin Shahrokni</td>
<td>FALLS IN OLDER CANCER PATIENTS UNDERGOING SURGERY: PREVALENCE AND ASSOCIATION WITH GERIATRIC SYNDROMES AND LEVELS OF DISABILITY ASSESSED IN PREOPERATIVE EVALUATION.</td>
</tr>
<tr>
<td>P048</td>
<td>Beatrice Edwards</td>
<td>FRACTURES IN OLDER CANCER PATIENTS, A CALL FOR ACTION</td>
</tr>
<tr>
<td>P049</td>
<td>Beatrice Edwards</td>
<td>NEUROCOGNITIVE PROFILE IN OLDER CANCER PATIENTS IN A GERIATRIC CLINIC</td>
</tr>
<tr>
<td>P050</td>
<td>Dagmara Poprawski</td>
<td>RESCUE GCS-F USE AS A MARKER OF SAFETY OF ANTI-CANCER TREATMENTS IN GERIATRIC PATIENTS IN REGIONAL AND RURAL SOUTH AUSTRALIA</td>
</tr>
<tr>
<td>P051</td>
<td>Daisuke Makiura</td>
<td>SARCOPEANIA IS ASSOCIATED WITH AN UNPLANNED READMISSION AND WORSE SURVIVAL FOLLOWING ESOPHAGECTOMY</td>
</tr>
<tr>
<td>P052</td>
<td>Der Sheng Sun</td>
<td>CLINICAL IMPLICATION OF BODY MASS INDEX, SKELETAL MASS INDEX AND RELATED BLOOD MARKERS IN THE ELDERLY PATIENTS WITH SOLID TUMORS</td>
</tr>
<tr>
<td>P053</td>
<td>Anita O’Donovan</td>
<td>THE BEHAVIORAL AND PSYCHOLOGICAL OUTCOMES OF CANCER SURVIVORS. RESULTS FROM THE IRISH LONGITUDINAL STUDY ON AGEING.</td>
</tr>
<tr>
<td>P054</td>
<td>Gouri Shankar Bhattacharyya</td>
<td>ASSESSMENT OF RENAL FUNCTION AMONG PATIENTS WITH BONE METASTASES FROM SOLID TUMORS</td>
</tr>
<tr>
<td>P055</td>
<td>Rafik Diab</td>
<td>PROPHYLACTIC USE OF FILGRASTIM TO MANAGE CHEMOTHERAPY-INDUCED NEUTROPENIA IN ELDERLY PATIENTS</td>
</tr>
<tr>
<td>P056</td>
<td>Karlijn Schulkes</td>
<td>CHEMOTHERAPY AND HEALTH CARE UTILISATION NEAR THE END OF LIFE IN PATIENTS WITH LUNG CANCER</td>
</tr>
<tr>
<td>P057</td>
<td>Lella Bengrine Lefevre</td>
<td>MANAGEMENT OF ELDERLY PATIENTS SUFFERING FROM CANCER: ASSESSMENT OF PERCEIVED BURDEN AND QUALITY OF LIFE OF PRINCIPAL CARER</td>
</tr>
<tr>
<td>P058</td>
<td>Ludmila Koch</td>
<td>NEUTROPHIL ENGRAFTMENT AND GRAFT-VERSUS-HOST DISEASE IN ELDERLY PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPORTANCE OF BODY COMPOSITION ASSESSMENT AND GERIATRIC</td>
</tr>
<tr>
<td>P059</td>
<td>Matti Aapro</td>
<td>EFFICACY AND SAFETY OF ROLAPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS AGED &lt;65 VERSUS ≥65 YEARS RECEIVING MULTIPLE CYCLES OF EMETOGENIC CHEMOTHERAPY</td>
</tr>
<tr>
<td>P060</td>
<td>Meghan Karuturi</td>
<td>POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY BREAST AND COLORECTAL CANCER PATIENTS</td>
</tr>
<tr>
<td>P061</td>
<td>Elena Paillaud</td>
<td>POTENTIAL DRUG INTERACTIONS IN OLDER PATIENTS WITH CANCER: THE ELCAPA COHORT SURVEY (ELCAPA-15)</td>
</tr>
</tbody>
</table>

## TRACK 4: MODERN DIAGNOSTICS AND THERAPEUTIC AREAS

<table>
<thead>
<tr>
<th>Abstract final identifier</th>
<th>Presenting author</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P063</td>
<td>Anita O’Donovan</td>
<td>APPLICATION OF ADEPT (A PROCESS FOR DECISION-MAKING AFTER PILOT AND FEASIBILITY TRIALS) TO A PILOT GERIATRIC ONCOLOGY PROGRAMME IN RADIATION THERAPY</td>
</tr>
<tr>
<td>P064</td>
<td>Anthea Cree</td>
<td>RADICAL RADIOTHERAPY IN PATIENTS AGED OVER 80 - A SINGLE UK CENTRE EXPERIENCE</td>
</tr>
<tr>
<td>P065</td>
<td>Armin Shahrokni</td>
<td>HIDDEN PREOPERATIVE GERIATRICS SYNDROMES IN PATIENTS WITH AMERICAN SOCIETY OF ANESTHESIOLOGISTS CLASS III</td>
</tr>
<tr>
<td>P066</td>
<td>AS Pericac</td>
<td>THE USE OF DOSE-DENSE WEEKLY PACLITAXEL (WP) CHEMOTHERAPY IN GERIATIC PATIENTS WITH GYNAECOLOGICAL CANCERS</td>
</tr>
<tr>
<td>P067</td>
<td>Aylin Nuhoglu Savas</td>
<td>THE EFFECT OF AGE ON PATIENT REPORTED OUTCOMES FOLLOWING RADICAL PROSTATE RADIOTHERAPY</td>
</tr>
<tr>
<td>P068</td>
<td>Bastien Cabarrou</td>
<td>HOW TO ADDRESS THE HETEROGENEITY IN THE DESIGN OF PHASE II CLINICAL TRIALS IN GERIATIC ONCOLOGY?</td>
</tr>
<tr>
<td>P070</td>
<td>Elisabeth Johanna Driessen</td>
<td>HOME BASED PREHABILITATION AND REHABILITATION TO OPTIMIZE PHYSICAL FITNESS AND TREATMENT OUTCOME IN PATIENT WITH NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW</td>
</tr>
<tr>
<td>P071</td>
<td>Gerald Sokol</td>
<td>ECHOCARDIOGRAPHIC EVALUATION OF CARDIOTOXIC DRUGS IN GERIATIC CANCER PATIENTS - BEYOND EJECTION FRACTION</td>
</tr>
</tbody>
</table>
## TRACK 4: MODERN DIAGNOSTICS AND THERAPEUTIC AREAS

<table>
<thead>
<tr>
<th>Abstract final identifier</th>
<th>Presenting author</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P072</td>
<td>Hans Wildiers</td>
<td>PROSPECTIVE COHORT STUDY FROM THE EORTC (1221-ETF) ON THE OCCURRENCE OF CANCER EVENTS IN BELGIAN NURSING HOME RESIDENTS (NHR).</td>
</tr>
<tr>
<td>P073</td>
<td>Ishwaria Mohan Subbiah</td>
<td>CLINICAL BENEFIT RATE AND PARTICIPATION OF PATIENTS WITH ADVANCED CANCER ON PHASE I CLINICAL TRIALS: A COMPARATIVE ANALYSIS OF SENIOR ADULTS AGED 65 YEARS AND ABOVE VERSUS MIDDLE AGE AND AYA PATIENTS.</td>
</tr>
<tr>
<td>P074</td>
<td>Jacqueline Wallage</td>
<td>EPIDURAL BASED ANESTHESIA FOR FRAIL ELDERLY PATIENTS IN BREAST CANCER SURGERY: METHOD OF CHOICE?</td>
</tr>
<tr>
<td>P075</td>
<td>Leila Bengrine Lefevre</td>
<td>MAY THERAPEUTIC DRUG MONITORING OF 5FU DECREASE TOXICITY IN ELDERLY? A RETROSPECTIVE STUDY</td>
</tr>
<tr>
<td>P076</td>
<td>Mary Denholm</td>
<td>OLDER PATIENTS RECEIVING CHEMOTHERAPY: CHARACTERISING THE POPULATION</td>
</tr>
<tr>
<td>P077</td>
<td>Michael Jaklitsch</td>
<td>SALVAGE SURGERY OF NON-SMALL CELL LUNG CANCER IN ELDERLY PATIENTS WITH PREVIOUS WEDGE RESECTION OR LOBECTOMY</td>
</tr>
<tr>
<td>P078</td>
<td>Frédérique Rousseau</td>
<td>EPITOP-01: ELDERLY CANCER PATIENTS, SAFETY AND QUALITY OF LIFE UNDER IMMUNOTHERAPIES: A PHASE IV TRIAL</td>
</tr>
<tr>
<td>P079</td>
<td>Theodora Karnakis</td>
<td>PREDICTORS OF POSTOPERATIVE COMPLICATIONS IN ELDERLY PATIENTS AGED 80 YEARS OR OLDER UNDERGOING CANCER SURGERY</td>
</tr>
<tr>
<td>P080</td>
<td>Joseph Kattan</td>
<td>TREATMENT OF CHEMO-RESISTANT CANCERS IN THE ELDERLY POPULATION: ROLE OF MOLECULAR TUMOR PROFILING.</td>
</tr>
<tr>
<td>P081</td>
<td>Vérène Dougoud-Chauvin</td>
<td>USING BIG DATA IN ONCOLOGY TO PROSPECTIVELY IMPACT CLINICAL PATIENT CARE: A PROOF OF CONCEPT STUDY</td>
</tr>
</tbody>
</table>

## TRACK 5: GERIATRIC ASSESSMENT, NURSING/ALLIED HEALTH AND SOCIO-ECONOMIC ISSUES

<table>
<thead>
<tr>
<th>Abstract final identifier</th>
<th>Presenting author</th>
<th>ABSTRACT TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P082</td>
<td>Allison Loucks</td>
<td>GERIATRIC ONCOLOGY NEEDS ASSESSMENT OF GENITOURINARY CANCER SITE GROUP: THE GERIATRIC ONCOLOGY DEMONSTRATION PROJECT</td>
</tr>
<tr>
<td>P083</td>
<td>Amina Ahmed</td>
<td>PRE-OPERATIVE ASSESSMENT AND POST-OPERATIVE OUTCOMES OF ELDERLY WOMEN WITH GYNECOLOGIC CANCERS: PRIMARY ANALYSIS OF NRG CC-002</td>
</tr>
<tr>
<td>P084</td>
<td>Ana Lumi Kanaji</td>
<td>PREDICTION OF FUNCTIONAL DECLINE AND 1 YEAR SURVIVAL IN ELDERLY CANCER PATIENTS USING COMPREHENSIVE GERIATRIC ASSESSMENT</td>
</tr>
<tr>
<td>P085</td>
<td>Andrea Luciani</td>
<td>CLINICAL RELEVANCE OF ONCOLOGICAL DIAGNOSIS IN FRAIL ELDERLY PATIENTS</td>
</tr>
<tr>
<td>P086</td>
<td>Andrew Edward Chapman</td>
<td>EVALUATION OF PATIENT PERCEPTIONS OF TEAM BASED CARE IN A GERIATRIC ONCOLOGY MULTIDISCIPLINARY INTERPROFESSIONAL CLINIC</td>
</tr>
<tr>
<td>P087</td>
<td>Anna Mazzeo</td>
<td>A CHALLENGE IN ONCOCGERIATRICS: IS ROCKWOOD FRAILTY INDEX AN ACCURATE TOOL TO PREDICT CLINICAL OUTCOMES?</td>
</tr>
<tr>
<td>P088</td>
<td>Antonella Brunello</td>
<td>THE ONCOLOGICAL MULTIDIMENSIONAL PROGNOSTIC INDEX (ONCO-MPI) HELPS PREDICTING BENEFITS OF TREATMENT FOR PATIENTS WITH ADVANCED COLORECTAL CANCER: A PROSPECTIVE SINGLE CENTER STUDY</td>
</tr>
<tr>
<td>P091</td>
<td>Cindy Kenis</td>
<td>FUNCTIONAL DECLINE IN OLDER PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY: A MULTICENTER PROSPECTIVE STUDY</td>
</tr>
<tr>
<td>P092</td>
<td>Claudia Margarita Martinez-Tapia</td>
<td>SCREENING FOR MULTIDIMENSIONAL HEALTH PROBLEMS IN OLDER PATIENTS WITH CANCER: EFFECT OF VARYING GOLD STANDARD DEFINITIONS ON THE DIAGNOSTIC PERFORMANCE OF THE GB AND MODIFIED GB SCREENING TOOLS</td>
</tr>
<tr>
<td>P093</td>
<td>Daneng Li</td>
<td>A RANDOMIZED CONTROLLED TRIAL OF GERIATRIC ASSESSMENT GUIDED MULTIDISCIPLINARY INTERVENTIONS: THE FIRST YEAR EXPERIENCE</td>
</tr>
<tr>
<td>P095</td>
<td>Daniel W. Yokom</td>
<td>EVALUATION OF THE GB, VES-13 AND FRIED FRAILTY CRITERIA AS SCREENING TOOLS FOR MULTIDIMENSIONAL HEALTH PROBLEMS IN PATIENTS ENROLLED IN A PHASE II TRIAL OF GERIATRIC ASSESSMENT AND MANAGEMENT FOR OLDER ADULTS WITH CANCER</td>
</tr>
<tr>
<td>P096</td>
<td>Davide Zattoni</td>
<td>EFFECTIVENESS OF THE FLEMISH VERSION OF TRIAGE RISK SCREENING TOOL IN DETECTING FRAILTY IN ELDERLY PATIENTS UNDERGOING EMERGENCY SURGERY: A PILOT STUDY.</td>
</tr>
<tr>
<td>Abstract final identifier</td>
<td>Presenting author</td>
<td>ABSTRACT TITLE</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>P097</td>
<td>Elisabeth Carola</td>
<td>DESCRIPTIVE ANALYSIS OF THE ONCOGERIATRIC COHORT OF PICARDY (COPAGE): CORRELATION BETWEEN G8 AND THE BALDUCCI SCORE.</td>
</tr>
<tr>
<td>P098</td>
<td>Ella H.C. Van Den Hout</td>
<td>STUDY PROTOCOL: GERIATRIC SCREENING TOOLS AND THE OUTCOME OF TREATMENT IN ONCOGERIATRIC PATIENTS</td>
</tr>
<tr>
<td>P099</td>
<td>Emilie Ferrat</td>
<td>PERFORMANCE OF FOUR FRAILTY CLASSIFICATIONS IN OLDER PATIENTS WITH CANCER: PROSPECTIVE ELCAPA COHORT STUDY</td>
</tr>
<tr>
<td>P100</td>
<td>Enrique Soto-Perez-De-Celis</td>
<td>A PILOT STUDY OF AN ACCELERATOR EQUIPPED SMARTPHONE TO MONITOR OLDER ADULTS WITH CANCER RECEIVING CHEMOTHERAPY IN MEXICO</td>
</tr>
<tr>
<td>P101</td>
<td>Eva Bustamante Maldonado</td>
<td>IMPLEMENTATION OF A GERIATRIC ONCOLOGY UNIT TO HELP OLDER CANCER PATIENTS WITH DECISION-MAKING</td>
</tr>
<tr>
<td>P102</td>
<td>Heike Schmidt</td>
<td>TRANS SECTORAL CARE OF GERIATRIC CANCER PATIENTS BASED ON COMPREHENSIVE GERIATRIC ASSESSMENT AND PATIENT-REPORTED QUALITY OF LIFE</td>
</tr>
<tr>
<td>P103</td>
<td>Imke Ortland</td>
<td>EVALUATION OF TWO ONCO-GERIATRIC SCORE SYSTEMS FOR PREDICTION OF THERAPY-ASSOCIATED TOXICITY IN ELDERLY CANCER PATIENTS</td>
</tr>
<tr>
<td>P104</td>
<td>Jakub Kenig</td>
<td>FOUR MODELS OF FRAILTY IN COLORECTAL CANCER PATIENTS QUALIFIED FOR ELECTIVE SURGERY.</td>
</tr>
<tr>
<td>P105</td>
<td>Jean-Pierre Droz</td>
<td>IMPLEMENTATION OF THE G8 SCREENING TOOLS IN A PUBLIC HOSPITAL IN FRENCH GUIANA</td>
</tr>
<tr>
<td>P106</td>
<td>Jelena Hajder</td>
<td>FUNCTIONAL DEPENDANCY IS PREDICTIVE FOR NUTRITIONAL STATUS IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES</td>
</tr>
<tr>
<td>P107</td>
<td>John Shen</td>
<td>COMPARING TRADITIONAL PERFORMANCE STATUS ASSESSMENT WITH MOBILE HEALTH ACTIVITY DATA AS A MEASURE OF FUNCTION</td>
</tr>
<tr>
<td>P108</td>
<td>Jurema Telles de Oliveira Lima Sales</td>
<td>QUALITY OF LIFE AND EARLY MORTALITY IN OLDER CANCER PATIENTS</td>
</tr>
<tr>
<td>P109</td>
<td>Jurema Telles de Oliveira Lima Sales</td>
<td>THE USE A COMPREHENSIVE GERIATRIC ASSESSMENT TO SEARCH FOR FACTORS ASSOCIATED WITH HIGHER RISK OF SHORT-TERM QUALITY OF LIFE.</td>
</tr>
<tr>
<td>P110</td>
<td>Katieen Fagard</td>
<td>VALUE OF GERIATRIC SCREENING AND ASSESSMENT IN PREDICTING POSTOPERATIVE COMPLICATIONS IN PATIENTS OLDER THAN 70 YEARS UNDERGOING SURGERY FOR COLORECTAL CANCER.</td>
</tr>
<tr>
<td>P111</td>
<td>Lene Kirkhus</td>
<td>FRAILTY AND SURVIVAL IN OLD PATIENTS WITH CANCER; CLINICAL JUDGMENT AND SYSTEMATIC GERIATRIC ASSESSMENTS</td>
</tr>
<tr>
<td>P112</td>
<td>Lore Decoster</td>
<td>A PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE USE OF BEVACIZUMAB AND CONVENTIONAL CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL (MCRC) PATIENTS: SCREENING AND GERIATRIC ASSESSMENT (GA).</td>
</tr>
<tr>
<td>P113</td>
<td>Manuela Bernardo</td>
<td>CANCER SURVIVORSHIP AND AGING - IS IT SO DIFFERENT FOR ELDERLY AND YOUNG?</td>
</tr>
<tr>
<td>P114</td>
<td>Rabia Boulahssass</td>
<td>EVALUATION OF THE IMPACT OF COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IN OLDER PATIENTS WITH KIDNEY CANCER</td>
</tr>
<tr>
<td>P115</td>
<td>Martine Puts</td>
<td>SENIOR TORONTO ONCOLOGY PANEL – RESEARCH PARTICIPATION FOR OLDER ADULTS WITH CANCER AND FAMILY MEMBERS/CAREGIVERS</td>
</tr>
<tr>
<td>P116</td>
<td>Martine Puts</td>
<td>CHEMOTHERAPY TREATMENT DECISION-MAKING EXPERIENCES OF OLDER ADULTS WITH CANCER, THEIR FAMILY MEMBERS, CANCER SPECIALISTS AND FAMILY PHYSICIANS: A MIXED METHODS STUDY</td>
</tr>
<tr>
<td>P117</td>
<td>Martine Puts</td>
<td>DEVELOPING A NATIONAL AGENDA ON CANCER AND AGING: THE CANADIAN NETWORK ON AGING AND CANCER (CNAC)</td>
</tr>
<tr>
<td>P118</td>
<td>Mary Denholm</td>
<td>EVALUATION OF DIAGNOSTIC PATHWAYS FOR OLDER PEOPLE WITH SUSPECTED CANCER: AN ANALYSIS OF A RAPID ACCESS GERIATRIC ASSESSMENT SERVICE</td>
</tr>
<tr>
<td>P119</td>
<td>Matthew Neve</td>
<td>IMPACT OF GERIATRIC ASSESSMENT ON THE MANAGEMENT OF OLDER ADULTS WITH HEAD AND NECK CANCER: A PILOT STUDY</td>
</tr>
<tr>
<td>P120</td>
<td>Matthieu Frasca</td>
<td>ALTERATION OF DOMAINS IN COMPREHENSIVE GERIATRIC ASSESSMENTS AND SURVIVAL IN A FRENCH MULTICENTER COHORT OF ELDERLY PATIENTS WITH CANCER</td>
</tr>
<tr>
<td>P121</td>
<td>Olivia Le Saux</td>
<td>PREHABILITATION AND REHABILITATION IN ONCOGERIATRICS: ADAPTATION TO DISEASE AND ACCOMPANIMENT OF PATIENTS’ TRAJECTORIES</td>
</tr>
<tr>
<td>P122</td>
<td>Peggy Sue Burhenn</td>
<td>EDUCATING 400 NURSES IN GERIATRIC ONCOLOGY ACROSS THE US (FUNDED BY THE NATIONAL INSTITUTE OF HEALTH #R25CA183723-01A1)</td>
</tr>
<tr>
<td>Abstract final identifier</td>
<td>Presenting author</td>
<td>ABSTRACT TITLE</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>P123</td>
<td>Penny Howard</td>
<td>FACTORS INFLUENCING TREATMENT DECISIONS MADE BY OLDER WOMEN WITH PRIMARY BREAST CANCER</td>
</tr>
<tr>
<td>P124</td>
<td>Prunella Blinman</td>
<td>CHEMOTHERAPY PRESCRIBING FOR OLDER ADULTS WITH CANCER: A SURVEY OF AUSTRALIAN ONCOLOGISTS</td>
</tr>
<tr>
<td>P125</td>
<td>Prunella Blinman</td>
<td>ESTIMATING THE RISK OF SEVERE CHEMOTHERAPY TOXICITY IN ADULTS ≥65 YEARS: COMPARING THE CARG SCORE WITH ONCOLOGISTS’ ESTIMATES OF TOXICITY</td>
</tr>
<tr>
<td>P126</td>
<td>Ramona Moor</td>
<td>IMPACT OF A WEEKLY MULTIDISCIPLINARY GERIATRIC ONCOLOGY MEETING ON THERAPEUTIC MANAGEMENT OF OLDER PATIENTS WITH CANCER.</td>
</tr>
<tr>
<td>P127</td>
<td>Rana Jin</td>
<td>DOES THE VULNERABLE ELDERLY SURVEY (VES-13) CORRELATE WITH THE PRESENCE OF GERIATRIC ISSUES AND SYNDROMES IN OLDER ADULTS WITH GENITOURINARY CANCER?</td>
</tr>
<tr>
<td>P128</td>
<td>Rana Jin</td>
<td>FEASIBILITY OF INTRODUCING VULNERABILITY SCREENING IN AN AMBULATORY CANCER CLINIC</td>
</tr>
<tr>
<td>P129</td>
<td>Rob Morris</td>
<td>THE EFFECT OF COMPREHENSIVE GERIATRIC ASSESSMENT ON TREATMENT DECISIONS AND MORTALITY AMONGST OLDER PATIENTS TREATED FOR UPPER GASTROINTESTINAL CANCER.</td>
</tr>
<tr>
<td>P130</td>
<td>Siran M. Koroukian</td>
<td>MULTIMORBIDITY AND HEALTH OUTCOMES IN OLDER ADULTS: A FOCUS ON CANCER SURVIVORS</td>
</tr>
<tr>
<td>P131</td>
<td>Siran M. Koroukian</td>
<td>TRAJECTORIES OF FUNCTIONAL LIMITATIONS AND HEALTH STATUS BY CANCER SURVIVOR STATUS: DOES THE GAP CLOSE WITH LONGER SURVIVORSHIP?</td>
</tr>
<tr>
<td>P132</td>
<td>Soha Ahrari</td>
<td>BARRIERS TO GOOD MEDICATION TAKING BEHAVIOUR IN METASTATIC PROSTATE CANCER PATIENTS RECEIVING ORAL ANTI-ANDROGEN THERAPY</td>
</tr>
<tr>
<td>P133</td>
<td>Stephanie Dauphin</td>
<td>THE DEVELOPMENT OF DISTRESS IN OLDER PATIENTS WITH CANCER IN THE MID-LONG TERM</td>
</tr>
<tr>
<td>P134</td>
<td>Tania Kalsi</td>
<td>THE UK GERIATRIC ONCOLOGY EXPERT REFERENCE GROUP (ERG) CONSENSUS ON CGA SCREENING</td>
</tr>
<tr>
<td>P135</td>
<td>Tania Kalsi</td>
<td>ONCOLOGICAL METHODS AND SERVICES FOR OLDER PEOPLE WITH CANCER: A NATIONAL SURVEY</td>
</tr>
<tr>
<td>P136</td>
<td>Theodora Karnakis</td>
<td>THE LONGITUDINAL USE OF GERIATRIC ASSESSMENT IN AN ONCOLOGY CENTER IN BRAZIL: A PILOT STUDY IN PATIENTS WITH BREAST CANCER</td>
</tr>
<tr>
<td>P137</td>
<td>Theodora Karnakis</td>
<td>ASSESSMENT OF OLDER PATIENTS WITH CANCER: EDMONTON FRAIL SCALE (EFS) AS A PREDICTOR OF ADVERSE OUTCOMES IN OLDER PATIENTS UNDERGOING RADIOTherapy</td>
</tr>
<tr>
<td>P138</td>
<td>Lorna Keenan</td>
<td>TRAINING MEDICAL ONCOLOGISTS TO ADDRESS THE NEEDS OF AGING CANCER PATIENTS</td>
</tr>
<tr>
<td>P139</td>
<td>Tina Hsu</td>
<td>GERIATRIC RESEARCH POLICY OF THE JAPAN CLINICAL ONCOLOGY GROUP</td>
</tr>
<tr>
<td>P140</td>
<td>Tomonori Mizutani</td>
<td>COUPLEs COPING WITH CANCER IN THE PLATINUM STAGE OF LIFE: OLDEST-OLD AND THEIR SPOUSAL CAREGIVERS</td>
</tr>
<tr>
<td>P142</td>
<td>Yasmin Raza</td>
<td>THE ROLE OF THE SOCIAL WORKER IN A COMPREHENSIVE GERIATRIC ASSESSMENT CLINIC FOR OLDER PEOPLE WITH UPPER GASTROINTESTINAL CANCER</td>
</tr>
<tr>
<td>P144</td>
<td>Elena Paillaud</td>
<td>DIALOG TASK FORCE FOR DEFINITION OF A GERIATRIC MINIMUM DATA SET FOR CLINICAL ONCOLOGY RESEARCH</td>
</tr>
</tbody>
</table>

*Please note that the following posters have been withdrawn: P006, P019, P046, P047, P062, P069, P073, P089, P090, P094.*
The broad perspective on a growing challenge

Gerontology

International Journal of Experimental, Clinical, Behavioural, Regenerative and Technological Gerontology

Editor: G. Wick (Innsbruck)

www.karger.com/ger

The book series

Interdisciplinary Topics in Gerontology and Geriatrics

Series Editor: Fulop, T. (Sherbrooke, Que.)

Vol. 42

HIV and Aging
Editors: Brannan-Ing, M. (New York, N.Y.); DeMarco, R. (Boston, Mass.)
Will be published 4th quarter 2016
Prepublication offer: CHF 88.00 / EUR 82.00 / USD 104.00
approx. List price: CHF 180.00 / EUR 168.00 / USD 212.00

Vol. 41

Frailty in Aging
Biological, Clinical and Social Implications
Editors: Theou, O. (Halifax, N.S.); Rockwood, K. (Halifax, N.S.)
X + 202 p., 22 fig., 6 tab., 2015
CHF 180.00 / EUR 168.00 / USD 212.00.

Vol. 40

Aging and Health – A Systems Biology Perspective
Editors: Yashin, A.I. (Durham, N.C.); Jazwinski, S.M. (New Orleans, La.)
XII + 194 p., 36 fig., 8 in color, 9 tab., 2015
CHF 180.00 / EUR 168.00 / USD 212.00. ISBN 978–3–318–02729–7 (hard cover)

Vol. 39

Aging
Facts and Theories
Editors: Robert, L. (Paris); Fulop, T. (Sherbrooke, Que.)
VIII + 216 p., 32 fig., 9 tab., 2014
CHF 196.00 / EUR 183.00 / USD 231.00. ISBN 978–3–318–02652–8 (hard cover)

www.karger.com/intgg

To keep up-to-date on what is being published in gerontology, subscribe to our Alert-Service at www.karger.com/mykarger
Sponsors acknowledgement

The International Society of Geriatric Oncology thanks all sponsors and exhibitors for their support towards the 2016 Annual Conference.

Gold sponsors

Janssen Oncology
Sanofi Genzyme

Bronze sponsors

Astellas
Celgene
MSD
Pierre Fabre Médicament
Pfizer

Conference supporter

Genomic Health

Educational grants

We gratefully acknowledge the following companies for their unrestricted educational grants towards our scientific programme.

This following session has been supported by an unrestricted educational grant from Astellas.

DAY 1 - Thursday, November 17, 2016

Washington B

16:30-17:45 Quality of life in geriatric population: why, what and how? Chairs: Florian Scotté (FR) and Siri Rostoft (NO)

16:30-16:43 Daily living with cancer: the patient’s voice
Susan Knox (IT)

16:43-16:56 Are patient reported outcomes programmes adapted to the geriatric population?
Paolo Bossi (IT)

16:56-17:09 Are tools the right way to assess quality of life in elderly?
Ulrich Wedding (DE)

17:09-17:21 Quality of life management: yes, we need guidelines!
Florian Scotté (FR)

17:21-17:45 Debate amongst speakers and audience

DAY 2 - Friday, November 18, 2016

This following session has been supported by an unrestricted educational grant from Janssen.

Washington B

14:15-15:45 Geriatric assessment to stratify treatment of older cancer patients Chairs: Arti Hurria (US) and Alessandra Larocca (IT)

14:15-14:33 Prostate cancer
Heather Payne (GB)

14:33-14:51 CLL
Paolo Ghia (IT)

14:51-15:09 Multiple myeloma
Alessandra Larocca (IT)

15:09-15:27 Haematology
Reinhard Stauder (AT)

15:27-15:45 Discussion and questions

Official media partners

Elsevier
ecancer.org
Industry sponsored satellite session programme

**DAY 1 - Thursday, November 17, 2016**

**Sanofi Genzyme sponsored symposium**

Room Washington B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-12:30</td>
<td>Improving the management of senior adults with prostate cancer</td>
<td>Matti Aapro (CH)</td>
</tr>
<tr>
<td>11:00-11:05</td>
<td>Welcome and introduction</td>
<td></td>
</tr>
<tr>
<td>11:05-11:20</td>
<td>Are we managing baby boomers with prostate cancer in the right way?</td>
<td>Matti Aapro (CH)</td>
</tr>
<tr>
<td>11:20-11:40</td>
<td>Optimizing the management of localized prostate cancer in senior adults</td>
<td>Nicolas Mottet (FR)</td>
</tr>
<tr>
<td>11:40-12:00</td>
<td>New horizons in advanced prostate cancer</td>
<td>Cora Sternberg (IT)</td>
</tr>
<tr>
<td>12:00-12:20</td>
<td>Updated SIOG guidelines for the management of senior adults with advanced prostate cancer</td>
<td>Jean-Pierre Droz (FR)</td>
</tr>
<tr>
<td>12:20-12:30</td>
<td>Discussion and closing remarks</td>
<td></td>
</tr>
</tbody>
</table>

**DAY 2 - Saturday, November 19, 2016**

**Celgene sponsored symposium**

Room Washington B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:30</td>
<td>Nanoparticle Albumin Bound (nab) paclitaxel and its role in the elderly: moving from clinical studies to clinical practice</td>
<td></td>
</tr>
<tr>
<td>10:30-10:35</td>
<td>Welcome and introduction</td>
<td>Laura Biganzoli (co-chair) (IT)</td>
</tr>
<tr>
<td>10:35-10:45</td>
<td>Improving outcomes for elderly patients with solid tumours</td>
<td>Lodovico Balducci (co-chair) (US)</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td>Nab-paclitaxel in the elderly: A focus on pancreatic, NSCLC and breast cancer:</td>
<td>Cesare Gridelli (IT)</td>
</tr>
<tr>
<td></td>
<td>Lung cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pancreatic cancer</td>
<td>Stefano Cascinu (IT)</td>
</tr>
<tr>
<td></td>
<td>Breast cancer</td>
<td>Laura Biganzoli (IT)</td>
</tr>
<tr>
<td>11:15-11:25</td>
<td>Q&amp;A</td>
<td>All faculty</td>
</tr>
<tr>
<td>11:25-11:30</td>
<td>Meeting summary and close</td>
<td>Lodovico Balducci (US)</td>
</tr>
</tbody>
</table>
Scientific displays at SIOG 2016

An open space within the poster area had been provided for industry partners to set-up a scientific display showcase. Come and join them during the coffee breaks which will take place in this open space promoting frequent and repeated opportunities for delegates to visit the posters and scientific displays.

**Exhibition opening hours**

- **Thursday, November 12**: 10:30-19:45
- **Friday, November 13**: 09:30-17:30
- **Saturday, November 14**: 09:30-15:00
Sponsor and exhibitor profiles

**AIOTE (Italian Society of Geriatric Oncology)**
Medical Oncology Unit, Umberto - Hospital, Siracusa, Italy - [www.aiote.net](http://www.aiote.net)
The aims of this society is (a) to promote training activities for both clinical oncologists and geriatricians, in order to improve their cooperation for a better management of elderly patients, (b) to increase the knowledge about cancer disease in elderly population, thus avoiding the discrimination of these patients who often receive inappropriate treatment, and, finally, (c) to educate elderly patients to cope better with the disease.

**Astellas**
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en)

**Celgene**
Route de Perreux 1,2017 Boudry, Switzerland - [www.celgene.com](http://www.celgene.com)
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. Celgene employs more than 7,000 employees worldwide.

**ecancer**
154 Cheltenham Road - Bristol - BS6 5RL - United Kingdom - [www.ecancer.org](http://www.ecancer.org)
ecancer is the leading oncology channel committed to improving cancer communication and education with the goal of optimising patient care and outcomes. We achieve this by publishing ecancer.org, a free online platform for oncology professionals incorporating an open-access journal, news, video and e-learning. All of our resources are available for free, are developed in partnership with leading experts and focus on supporting healthcare professionals to improve their practice behaviours. For cutting edge education from the world’s leading experts in oncology visit [www.ecancer.org](http://www.ecancer.org).

**Elsevier / Journal of Geriatric Oncology**
The Boulevard, Langford Lane, Kidlington - Oxford - OX5 1GB - United Kingdom - [www.elsevier.com](http://www.elsevier.com)
The Journal of Geriatric Oncology - published by Elsevier - the official journal of the International Society of Geriatric Oncology - is an international, multidisciplinary journal which is focused on advancing research in the treatment and survivorship issues of older adults with cancer, as well as literature relevant to education and policy development in geriatric oncology. Edited by Dr Arti Hurria, City of Hope, USA, the journal publishes original research articles, review articles, clinical trials, short communications and correspondence.
Genomic Health
Quai du Seujet 10, 3rd floor, 1201 Geneva, Switzerland - www.genomichealth.com
Genomic Health, Inc. is a world’s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of cancer. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit www.genomichealth.com

Janssen Pharmaceutica NV
Turnhoutseweg 30 - B-2340 Beerse - Belgium - www.janssen-emea.com
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases. Driven by our commitment to patients, Janssen develops innovative products, services and healthcare solutions to help people throughout the world. More information can be found at www.janssen-emea.com

Multinational Association of Supportive Care in Cancer (MASCC)
Herredsvejen 2 - DK-3400 Hillerød - Denmark - Phone +45 4820 7022 - Fax +45 4821 7022
www.mascc.org
The Multinational Association of Supportive Care in Cancer (MASCC) is an international, multidisciplinary Organization, dedicated to research and education in all areas of supportive care for patients with cancer. It involves a variety of disciplines and specialists. Thus membership is open to oncology medical, surgical, and radiology physicians, nurses, dentists, dental hygienists, pharmacists, social workers, and many others interested in supportive care in cancer.

Merck & Co., Inc.
2000 Galloping Hill Road, Kenilworth, NJ 07033, United States - www.msd.com
Today’s MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit www.msd.com

Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube, and like us on Facebook at Facebook.com/Pfizer.
Pierre Fabre Group
45, Place Abel Gance - Boulogne Billancourt 92654 - France - www.pierre-fabre.com
Pierre Fabre is a French multinational, privately-owned pharmaceutical and cosmetic company present in 130 countries. Pierre Fabre’s oncology know-how is based on decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. Pierre Fabre oncology R&D centers are Pierre Fabre Immunology Centre (CIPF) in Saint-Julien-en-Genevois, France and Pierre Fabre Research Institute (IRPF) in Toulouse, France. For more information on Pierre Fabre, please visit www.pierre-fabre.com

Sanofi Genzyme
54 Rue de la Boetie - 75008 Paris - France - www.sanofi.com
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

SIOG - International Society of Geriatric Oncology
1-5 Route des Morillons - P.O. Box 2100 - 1211 Geneva - Switzerland - www.siog.org
The International Society of Geriatric Oncology is a multidisciplinary society, including physicians in the fields of oncology and geriatrics, and allied health professionals and has over 1,500 members in more than 40 countries around the world. The major risk factor for cancer is age, and with the aging of the world population, a major epidemiologic challenge is before us. The mission of SIOG is to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment and care of older adults with cancer. Learn more about SIOG at www.siog.org
# Faculty disclosures

<table>
<thead>
<tr>
<th>First Name</th>
<th>Disclosure of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matti Aapro (CH)</td>
<td>No information received at the moment of printing</td>
</tr>
</tbody>
</table>
| Luca Arcaini (IT)          | - Consultancy: CELGENE, ROCHE, BAYER  
- Research funding: GILEAD  
- Advisory Board: ROCHE, CELGENE, GILEAD, SANDOZ*                                                                 |
| Lodovico Balducci (US)     | No information received at the moment of printing                                                                                                       |
| Gouri Shankar Bhattacharyya (IN) | The author has declared no conflict of interest                                                                                                           |
| Laura Biganzoli (IT)       | No information received at the moment of printing                                                                                                       |
| Paolo Bossi (IT)           | The author has declared no conflict of interest                                                                                                        |
| Etienne Brain (FR)         | - Research funding: TEVA (Cephalon), HalioDx (QIAGEN, Ipsogen)  
- Advisory role: Amgen, Roche, Pierre Fabre  
- Honoraria: GSK, TEVA, Roche, AstraZeneca                                                                 |
| Bruno Castagneto (IT)      | The author has declared no conflict of interest                                                                                                        |
| Kwok-Leung Cheung (GB)     | Advisory board for Genomic Health                                                                                                                       |
| Raul Cordoba (SP)          | No information received at the moment of printing                                                                                                       |
| Romain Corre (FR)          | The author has declared no conflict of interest                                                                                                        |
| Andrea Costanzi (IT)       | The author has declared no conflict of interest                                                                                                        |
| Nienke de Glas (NL)        | The author has declared no conflict of interest                                                                                                        |
| Jean-Pierre Droz (FR)      | The author has declared no conflict of interest                                                                                                        |
| Hassan Errihani (MO)       | The author has declared no conflict of interest                                                                                                        |
| Francesca Cerreta (BE)     | The author has declared no conflict of interest                                                                                                        |
| Marièle Filbet (FR)        | The author has declared no conflict of interest                                                                                                        |
| Lucia Fratino (IT)         | No information received at the moment of printing                                                                                                       |
| Tamas Fulop (CA)           | The author has declared no conflict of interest                                                                                                        |
| Paolo Ghia (IT)            | No information received at the moment of printing                                                                                                       |
| Marine Gilabert (FR)       | No information received at the moment of printing                                                                                                       |
| Cesare Gridelli (IT)       | No information received at the moment of printing                                                                                                       |
| Marije Hamaker (NL)        | The author has declared no conflict of interest                                                                                                        |
| Holly Holmes (US)          | The author has declared no conflict of interest                                                                                                        |
| Arti Hurria (US)           | Research support: Celgene, Novartis, and GSK. Consultant: Boehringer Ingelheim Pharmaceuticals, Carevive, Sanofi, and GTx, Inc.                   |
| Ravindran Kanesvaran (SG)  | The author has declared no conflict of interest                                                                                                        |
| Joseph Kaftan (LB)         | The author has declared no conflict of interest                                                                                                        |
| Karis Kin-Fong Cheng (SG)  | The author has declared no conflict of interest                                                                                                        |
| Susan Knox (IT)            | The author has declared no conflict of interest                                                                                                        |
| Ludmila Koch (BR)          | The author has declared no conflict of interest                                                                                                        |
| Lalit Krishna (SG)         | The author has declared no conflict of interest                                                                                                        |
| Ian Kunkler (GB)           | The author has declared no conflict of interest                                                                                                        |
| Marco Ladetto (IT)         | No information received at the moment of printing                                                                                                       |
| Alessandra Larocca (IT)    | No information received at the moment of printing                                                                                                       |
| Trine Lembrecht Jergensen (DK) | No information received at the moment of printing                                                                                                       |
| Stuart Lichtman (US)       | No information received at the moment of printing                                                                                                       |
| Laura Lozza (IT)           | No information received at the moment of printing                                                                                                       |
| Andrea Luciani (IT)        | The author has declared no conflict of interest                                                                                                        |
| Stefania Maggi (IT)        | The author has declared no conflict of interest                                                                                                        |
| Michele Maio (IT)          | The author has declared no conflict of interest                                                                                                        |
| Christos Markopoulos (GR)  | The author has declared no conflict of interest                                                                                                        |
| Christophe Massard (FR)    | Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer, Roche, Sanofi Orion |
## Faculty disclosures

<table>
<thead>
<tr>
<th>First Name</th>
<th>Disclosure of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Francesco Merli (IT)</td>
<td>The author has declared no conflict of interest</td>
</tr>
</tbody>
</table>
| Stefania Migliuolo (IT)     | In the role of CEO of an Healthcare communication agency, I had/have relationships with the following Pharmaceutical companies, creating and managing communication projects: 1. Novartis, 2. Pfizer, 3. PfizerCh, 4. Fidia, 5. Sanofi, 6. Menarini, 7. Gilead, 8. Merckxenro  
In the role of volunteer for Europa Donna, in medical and scientific congresses and meetings, I exclusively represent Europa Donna organization. |
| Olivier Mir (FR)            | No information received at the moment of printing                                                                                                        |
| Nicolas Mottet (FR)         | Travel grants / consultation fees from Pierre Fabre - Travel grants from Sanofi Pasteur.                                                                 |
| Arash Naeim (US)            | INVISTA Health Inc. (Founder and Shareholder), a company focused on remote monitoring of older individuals                                                   |
| Anita O’Donovan (IE)        | The author has declared no conflict of interest                                                                                                         |
| Rebecca Olin (US)           | The author has declared no conflict of interest                                                                                                         |
| Nina Ommundsen (NO)         | The author has declared no conflict of interest                                                                                                         |
| Roberto Orecchia (IT)       | The author has declared no conflict of interest                                                                                                         |
| Cécile Ortholan (MC)        | The author has declared no conflict of interest                                                                                                         |
| Demetris Papamichael (CY)   | No information received at the moment of printing                                                                                                        |
| Heather Payne (GB)          | The author has declared no conflict of interest                                                                                                         |
| Fausto Rolla (IT)           | No information received at the moment of printing                                                                                                        |
| Siri Rostoft (NO)           | The author has declared no conflict of interest                                                                                                         |
| Patrick Roth (CH)           | The author has declared no conflict of interest                                                                                                         |
| Florian Scotté (FR)         | No information received at the moment of printing                                                                                                        |
| Ponnandai Somasundar (US)   | The author has declared no conflict of interest                                                                                                         |
| Pierre Soubeynan (FR)       | No information received at the moment of printing                                                                                                        |
| Reinhard Stauder (AT)       | The author has declared no conflict of interest                                                                                                         |
| Richard Sullivan (GB)       | The author has declared no conflict of interest                                                                                                         |
| Kazuo Tamura (JP)           | The author has declared no conflict of interest                                                                                                         |
| William Tew (US)            | The author has declared no conflict of interest                                                                                                         |
| Clémence Thébaut (FR)       | The author has declared no conflict of interest                                                                                                         |
| Janice Tsang (CN)           | No information received at the moment of printing                                                                                                        |
| Giampaolo Ugolini (IT)      | No information received at the moment of printing                                                                                                        |
| Willeminen van de Water (NL)| No information received at the moment of printing                                                                                                        |
| Antonio Vigano (CA)         | The author has declared no conflict of interest                                                                                                         |
| Ulrich Wedding (DE)         | No information received at the moment of printing                                                                                                        |
| Tanya Wildes (US)           | No information received at the moment of printing                                                                                                        |
| Hans Wildiers (NL)          | Pfizer, Amgen, OncologyLive, PUMA, Roche, Janssen, Lilly, Leo Pharma, TRM Oncology, Novartis, Encore Medical, Teva |
| Annie Young (GB)            | No information received at the moment of printing                                                                                                        |
| Gilbert Zulian (CH)         | The author has declared no conflict of interest                                                                                                         |
Oncologists and Geriatricians need to work together! Here is how:

Join our unique CME accredited training programme lead by international experts in the field of geriatrics AND oncology designed to provide specific skills in assessment, care pathways and therapeutic choices about the elderly patients with cancer in order to provide the basis of the assessment and the multi-dimensional approach that should be applied to elderly cancer patients.

This 2-phase advanced course is addressed to professionals in the management of elderly cancer patients who will acquire knowledge on the general principles of cancer treatment as a multidisciplinarity with case based programmes, discussions and debates in geriatrics for clinical oncologists as well as in clinical oncology for geriatricians.

**Phase 1** 4-day course in Treviso, Italy from June 28-July 1, 2017

**Phase 2** 3 days at the SIOG 2016 Annual Conference in Warsaw, Poland from November 9-11, 2017

Join us in Treviso, find your mentor, be part of an international network and become the bridge between the oncological and geriatric teams in your institution.

Mark your calendar!

- Admission process opens January 9, 2017
- Admission process closes February 13, 2017
- Notification of acceptance beginning March 2017

Pending applications for auspices and endorsement:___________________________

Find out more and sign up at [www.siog.org](http://www.siog.org)

Places are limited!
17th Conference of the International Society of Geriatric Oncology

“From research to practice: incorporating geriatric oncology into patient care”

Save the date!

Scientific programme committee:

- Stuart Lichtman (US), Chair
- Demetris Papamichael (CY), Co-chair
- Agnieszka Jagiello-Gruszfeld (PL), Local chair
- Matti Aapro (CH), Chair, Corporate Relations Committee
- Ravindran Kanesvaran (SG)
- Siri Rostoft (NO)